Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
5-Amino-1MQ
Weight Management
Abarelix
Hormone Support
Acetyl Hexapeptide-3 (Argireline)
Cosmetic
Adipotide
Weight Management
Adrenomedullin
Healing & Recovery
Alexamorelin
Growth Hormone
Angiotensin (1-7)
Healing & Recovery
AOD-9604
Weight Management
Apelin-13
Healing & Recovery
ARA-290 (Cibinetide)
Healing & Recovery
Bestatin (Ubenimex)
Immune
BPC-157
Healing & Recovery
Buserelin
Hormone Support
Cagrilintide
Weight Management
CagriSema
Weight Management
Capromorelin
Growth Hormone
Cartalax
Anti-Aging
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Immune
Cerebrolysin
Cognitive
Cerluten
Cognitive
Cetrorelix
Hormone Support
Chonluten
Immune
CJC-1295 (No DAC)
Growth Hormone
CJC-1295 with DAC
Growth Hormone
Cortexin
Cognitive
Crystagen
Immune
Daptomycin
Immune
Defensin (HBD-2)
Immune
Defensin (HBD-3)
Immune
Degarelix
Hormone Support
Dihexa
Cognitive
DSIP (Delta Sleep-Inducing Peptide)
Sleep & Recovery
Dulaglutide
Weight Management
Enalapril
Healing & Recovery
Epithalon
Anti-Aging
Exenatide
Weight Management
Fertirelin
Hormone Support
FOXO4-DRI
Anti-Aging
Ganirelix
Hormone Support
GHK-Cu (Copper Peptide)
Cosmetic
GHRH (1-29)
Growth Hormone
GHRP-2
Growth Hormone
GHRP-6 (Growth Hormone Releasing Peptide-6)
Growth Hormone
Glutathione
Anti-Aging
Gonadorelin (GnRH)
Hormone Support
Gramicidin
Immune
Hexarelin
Growth Hormone
Human Chorionic Gonadotropin (HCG)
Hormone Support
Human Growth Hormone (HGH)
Growth Hormone
IGF-1 LR3
Growth Hormone
Immunoxel (Dzherelo)
Immune
Imunofan
Immune
Intermedin (Adrenomedullin-2)
Healing & Recovery
Ipamorelin
Growth Hormone
Kisspeptin-10
Sexual Health
KPV (Alpha-MSH Fragment)
Healing & Recovery
Lactoferricin B
Immune
Larazotide
Healing & Recovery
Lentinan
Immune
Leuphasyl
Cosmetic
Leuprolide
Hormone Support
Liraglutide
Weight Management
Livagen
Anti-Aging
Lixisenatide
Weight Management
LL-37
Immune
Macimorelin
Growth Hormone
Magainin-2
Immune
Mazdutide
Weight Management
Melanotan-2
Cosmetic
MK-677 (Ibutamoren)
Growth Hormone
MOTS-c
Metabolic
Myristoyl Pentapeptide-17
Cosmetic
N-Acetyl Selank
Cognitive
N-Acetyl Semax Amidate
Cognitive
NAD+
Mitochondrial
Nafarelin
Hormone Support
Natriuretic Peptide (ANP)
Healing & Recovery
Nesiritide (BNP)
Healing & Recovery
Nisin
Immune
Noopept (Omberacetam)
Cognitive
Orforglipron
Weight Management
Ovagen
Anti-Aging
Oxytocin Acetate
Hormone Support
P21 (P021)
Cognitive
PACAP-38
Healing & Recovery
Palmitoyl Oligopeptide
Cosmetic
Palmitoyl Pentapeptide-4 (Matrixyl)
Cosmetic
Palmitoyl Tetrapeptide-7
Cosmetic
Palmitoyl Tripeptide-1
Cosmetic
Pancragen
Metabolic
PEG-MGF
Healing & Recovery
Pemvidutide
Weight Management
Pentadecapeptide (BPC Analog)
Healing & Recovery
Pidotimod
Immune
Pinealon
Cognitive
PNC-27
Immune
Polymyxin B
Immune
Pralmorelin (GHRP-2)
Growth Hormone
Pramlintide
Weight Management
Prostamax
Hormone Support
PT-141 (Bremelanotide)
Sexual Health
Relaxin-2 (Serelaxin)
Healing & Recovery
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Setmelanotide
Weight Management
SLU-PP-332
Metabolic
SM-130686
Growth Hormone
Snap-8
Cosmetic
SS-31 (Elamipretide)
Mitochondrial
Substance P Antagonists
Healing & Recovery
Survodutide
Weight Management
SYN-AKE
Cosmetic
Tabimorelin
Growth Hormone
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Testagen
Hormone Support
Thymalin
Immune
Thymopentin (TP-5)
Immune
Thymopoietin
Immune
Thymosin Alpha-1
Immune
Thymosin Beta-4
Healing & Recovery
Thymulin (FTS)
Immune
Thymulin Analog (PAT)
Healing & Recovery
Tirzepatide
Weight Management
Tripeptide-29
Cosmetic
Triptorelin
Hormone Support
Ularitide
Healing & Recovery
Urocortin
Healing & Recovery
Ventfort
Anti-Aging
Vesilute
Hormone Support
Vilon
Immune
VIP (Vasoactive Intestinal Peptide)
Healing & Recovery
Xenin-25
Metabolic
Ziconotide (Prialt)
Healing & Recovery
Total Peptides: 137
Back to Home
Back to Semaglutide

Clinical trials

Every registered trial of Semaglutide

755 studies, 259 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Semaglutide has been studied in people a great deal.
  • 755 registered studies in total.
  • 259 are still enrolling people, so this is active research, not just history.

What kind of research

  • 637 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 236,836 people took part in those.
  • A further 118 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.

How far along it is

  • 268 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
  • 190 have published results in the medical literature that anyone can read.
  • The research spans 71 countries.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 755 of 755 trials for Semaglutide.

  • NCT07586150Not Yet Recruiting140 enrolled2028

    Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

    Ludwig-Maximilians - University of Munich

    Severe Mental Illness · Depression / Major Depressive Disorder · Bipolar Disorder (BD) · Schizophrenia

  • NCT07430332Phase 2Not Yet Recruiting15 enrolled2027

    GLP-1 RA for Stage 1 Type 1 Diabetes

    Children's Hospital Medical Center, Cincinnati

    Stage 1 Diabetes Mellitus, Type 1

  • NCT07711548Not Yet Recruiting292 enrolled2027

    Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?

    Knut Mai

    Obesity & Overweight · Weight Loss Maintenance

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07754045Phase 2Not Yet Recruiting202 enrolled2027

    Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

    Lumos Pharma

    Obesity & Overweight

  • NCT07731256Phase 2Not Yet Recruiting250 enrolled2027

    Semaglutide for Low Back Pain

    Washington University School of Medicine

    Lower Back Pain · Obesity (BMI>30) · Chronic Lower Back Pain · glp1 Agonist

  • NCT07614412Phase 2Not Yet Recruiting240 enrolled2027

    SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

    Ministry of Health, Saudi Arabia

    Type 1 Diabetes Mellitus

  • NCT07462663Phase 4Not Yet Recruiting80 enrolled2027

    SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

    Hospital Universitari de Bellvitge

    Endometrial Cancer · Endometrial Cancer Stage I · Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I · Atypical Endometrial Hyperplasia

  • NCT07787936Not Yet Recruiting150 enrolled2027

    GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

    Miedziowe Centrum Zdrowia SA

    Heart Failure With Preserved Ejection Fraction · Obesity · Diastolic Heart Failure · Pulmonary Hypertension

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07770282Phase 3Not Yet Recruiting600 enrolled2026

    Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome

    All India Institute of Medical Sciences, Bhubaneswar

    Schizophrenia Disorder · Metabolic Syndrome · Antipsychotic-induced Weight Gain · Cardiovascular Risk

  • NCT07760948Phase 2Not Yet Recruiting90 enrolled2026

    HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

    Vanderbilt University Medical Center

    Type 2 Diabetes Mellitus (T2DM) · Sarcopenia · Obesity · Muscle Loss

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06546384Not Yet Recruiting64 enrolled2026

    GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

    Insel Gruppe AG, University Hospital Bern

    Adiposity · Fatty Liver · Alcohol Use Disorder

  • NCT07389941Phase 4Not Yet Recruiting240 enrolled2026

    Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

    University of Luebeck

    Atrial Fibrillation (AF)

  • NCT06977438Phase 4Not Yet Recruiting1,020 enrolled2026

    GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward

    University of Minnesota

    Obesity, Childhood

  • NCT07772960Phase 1Not Yet Recruiting90 enrolled2026

    Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

    Yale University

    Alcohol Use Disorder (AUD) · Obesity (BMI Equal to or >30)

  • NCT07755085Phase 4Not Yet Recruiting100 enrolled2026

    GLP-1s in Hip and Knee Arthroplasty

    Nova Scotia Health Authority

    Arthritis · Obesity & Overweight · GLP - 1

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07737522Phase 2Not Yet Recruiting32 enrolled2026

    Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

    Imperial College London

    Pulmonary Arterial Hypertension

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07511543Phase 3Not Yet Recruiting826 enrolled2026

    Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

    Population Health Research Institute

    Ischemic Stroke

  • NCT07668414Phase 3Not Yet Recruiting650 enrolled2026

    A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT07713992Not Yet Recruiting72 enrolled2026

    Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide

    Tianjin Medical University

    Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus

  • NCT07770152Phase 4Not Yet Recruiting42 enrolled2026

    Semaglutide in Youth With Autism Spectrum Disorder

    Children's Hospital Medical Center, Cincinnati

    Autism Spectrum Disorder · Obesity

  • NCT07485062Phase 4Not Yet Recruiting164 enrolled2026

    Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes

    Western University, Canada

    Type 2 Diabetes · Cognitive Decline in Older Adults

  • NCT07642635Phase 1/2Not Yet Recruiting30 enrolled2026

    Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

    Vanderbilt University Medical Center

    Duchenne Muscular Dystrophy (DMD)

  • NCT07769047Phase 4Not Yet Recruiting50 enrolled2026

    Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

    Mayo Clinic

    Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8

  • NCT07783854Phase 4Not Yet Recruiting72 enrolled2026

    A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Obesity & Overweight

  • NCT07617155Phase 4Not Yet Recruiting396 enrolled2026

    GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

    Peking Union Medical College Hospital

    Hypertriglyceridemia Induced Acute Pancreatitis · Recurrent Acute Pancreatitis · Pancreatitis Relapsing · Hypertriglyceridemia

  • NCT07509112Phase 2Not Yet Recruiting40 enrolled2026

    Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

    Kirby Institute

    Methamphetamine Use Disorder

  • NCT07622810Phase 3Not Yet Recruiting352 enrolled2026

    BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

    Carnot Laboratories

    Obesity & Overweight

  • NCT07628985Phase 3Not Yet Recruiting374 enrolled2026

    BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

    Carnot Laboratories

    Type 2 Diabetes Mellitus (T2DM)

  • NCT07728812Not Yet Recruiting424 enrolled2026

    Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy

    Phenomix Sciences

    Obesity & Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • ISRCTN29694121240 enrolled2026

    Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (Smile T1D)

    University of Birmingham

    Type 1 diabetes

  • NCT07743983Phase 3Recruiting372 enrolled2026

    A Study of BGM0504 in Early T2DM With Obesity

    BrightGene Bio-Medical Technology Co., Ltd.

    Type 2 Diabetes (T2DM)

  • NCT07720466Not Yet Recruiting40 enrolled2026

    Salivary Function and Dental Changes During GLP-1 Therapy

    Bilecik Seyh Edebali Universitesi

    Obesity · Dental Erosion · Saliva Collection · Saliva Altered

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-523933-24-00Ongoing335 enrolled2026

    D7261C00005

    AstraZeneca AB

    type 2 diabetes mellitus

  • NCT07767175Phase 1Not Yet Recruiting142 enrolled2026

    A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT07770841Phase 3Recruiting450 enrolled2026

    Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Novo Nordisk A/S

    Overweight · Obesity

  • 2025-524626-18-00Ongoing315 enrolled2026

    NN9932-8687

    Novo Nordisk A/S

    Overweight and obesity

  • NCT07760532Not Yet Recruiting200 enrolled2026

    Comparing Facial Aging Between Identical Twins With 3D Imaging

    Ponsky Facial Aesthetics And Plastic Surgery, Llc

    Facial Skin Aging · Facial Volume Loss · Wrinkle Appearance

  • NCT07213323Recruiting50 enrolled2026

    Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment

    Hospices Civils de Lyon

    Obesity &Amp; Overweight · Digestive Disorders

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07745504Phase 3Not Yet Recruiting285 enrolled2026

    A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT07592546Phase 4Not Yet Recruiting240 enrolled2026

    Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

    Alain Dagher

    Class I/II Obesity

  • NCT07653477Phase 3Not Yet Recruiting956 enrolled2026

    Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

    The United Bio-Technology (Hengqin) Co., Ltd.

    Type 2 Diabetes

  • 2025-524738-24-00Ongoing70 enrolled2026

    R0126321A

    Radboud universitair medisch centrum Stichting

    Diabetic foot ulcer

  • NCT07218354Phase 3Recruiting622 enrolled2026

    Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    VA Office of Research and Development

    Alcohol Use Disorder

  • 2025-522488-14-00Ongoing1,140 enrolled2026

    NN9838-7910

    Novo Nordisk A/S

    Participants with obesity with or without type 2 diabetes

  • 2025-524612-11-00Ongoing100 enrolled2026

    SEMTOL 1.0

    University Of Tartu

    Overweight and obesity

  • NCT07732426Recruiting30 enrolled2026

    Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies

    Seoul National University Hospital

    Food Addiction Tendency · Obesity · Overweight

  • NCT07695454Not Yet Recruiting10 enrolled2026

    Imaging in Semaglutide Study

    The Cleveland Clinic

    Type 2 Diabetes · BMI Greater Than 30

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07627191Early Phase 1Not Yet Recruiting30 enrolled2026

    GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

    University of Arizona

    Pancreatic Cancer · Colorectal Cancer · Hepatocellular Carcinoma

  • NCT07662213Phase 3Recruiting1,200 enrolled2026

    A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT07651319Phase 1/2Recruiting30 enrolled2026

    Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    The Methodist Hospital Research Institute

    Alzheimer Dementia (AD)

  • NCT07411378Phase 2Not Yet Recruiting164 enrolled2026

    Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

    Biophytis

    Muscle Wasting · Obesity & Overweight · Obesity

  • NCT07677995Enrolling By Invitation60 enrolled2026

    Free Fatty Acid Effects In Type 2 Diabetes

    University of Ulster

    Type 2 Diabetes · Cardiovascular Disease · Omega-3 Fatty Acids

  • NCT07727473Early Phase 1Not Yet Recruiting20 enrolled2026

    Preoperative Semaglutide Prior to Radical Prostatectomy

    Banner Health

    Prostate Cancer

  • NCT07430059Phase 1Not Yet Recruiting20 enrolled2026

    Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

    Vivani Medical, Inc

    Obesity & Overweight

  • NCT07720414Recruiting18 enrolled2026

    Effects of GLP-1 RAs on Human Lactation Outcomes

    University of Colorado, Denver

    Lactation · Weight Loss

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-522326-13-00Ongoing122 enrolled2026

    Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial

    Region Hovedstaden

    Obesity defined by BMI equal to or higher than 30, Obesity defined by BMI equal to or higher than 27 and obesity-related diagnosis registered in the electronic patient journal such as: hypertension, hypercholesterolemia, dyslipidemia, micro albuminuria, ischemic heart disease, stroke, atherosclerosis or athrosis), Type 1 Diabetes

  • 2025-523511-11-00Ongoing268 enrolled2026

    K9531-3107

    Kailera Therapeutics Inc.

    Obesity

  • 2025-524177-16-00Ongoing22 enrolled2026

    An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.

    Institute Of Tropical Medicine

    Craving for and use of chemsex-related drugs

  • NCT07668388Phase 2Recruiting300 enrolled2026

    A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07728383Phase 4Recruiting40 enrolled2026

    A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

    Gila Therapeutics, Inc.

    Obesity & Overweight

  • NCT07673900Phase 1Recruiting62 enrolled2026

    Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

    Terrestrial Bio, Inc.

    Overweight and/or Obesity

  • NCT07613437Phase 2Not Yet Recruiting200 enrolled2026

    GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial

    Chinese University of Hong Kong

    Intracerebral Hemorrhage

  • NCT07021937Phase 3Not Yet Recruiting120 enrolled2026

    Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

    University of Colorado, Denver

    Obesity/Therapy

  • NCT07702461Recruiting300 enrolled2026

    Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

    Ohio State University

    Obesity & Overweight · Diabetes (DM)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07639021Phase 2Recruiting230 enrolled2026

    A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Novo Nordisk A/S

    Obesity

  • NCT07570810Not Yet Recruiting30 enrolled2026

    Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

    Shanghai Jiao Tong University School of Medicine

    Type 2 Diabetes · Obesity · Non-alcoholic Fatty Liver Disease

  • NCT07282769Phase 2Not Yet Recruiting10 enrolled2026

    Semaglutide (Wegovy) Treatment for Trichotillomania

    University of Chicago

    Trichotillomania (Hair-Pulling Disorder) · Trichotillomania · Hair Pulling Disorder · Hair Pulling

  • NCT06934655Phase 3Not Yet Recruiting150 enrolled2026

    Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

    Children's Hospital Los Angeles

    Pediatric Obesity · Metabolic and Bariatric Surgery · Semaglutide

  • NCT07621640Not Yet Recruiting80 enrolled2026

    Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)

    Hallym University

    Obesity · Metabolic Syndrome · Brown Adipose Tissue

  • NCT07444073Not Yet Recruiting440 enrolled2026

    Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

    National University of Singapore

    Aging · Obesity & Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-520446-31-00Ongoing440 enrolled2026

    NN9490-8028

    Novo Nordisk A/S

    Participants with overweight or obesity, and type 2 diabetes

  • NCT07564414Phase 3Recruiting2,500 enrolled2026

    A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    Novo Nordisk A/S

    Obesity · Type 2 Diabetes

  • NCT07400107Phase 3Not Yet Recruiting1,000 enrolled2026

    AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    Novo Nordisk A/S

    Obesity · Overweight · Diabetes Mellitus, Type 2

  • NCT07627074Recruiting35,000 enrolled2026

    Weight Loss in Adults Using Semaglutide (Real-world Study)

    Novo Nordisk A/S

    Overweight · Obesity

  • 2025-524163-21-00Ongoing100 enrolled2026

    A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

    Region Hovedstaden

    Cannabis dependence (Cannabis Use Disorder or CUD)

  • NCT07428746Phase 3Recruiting20 enrolled2026

    Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

    Emory University

    Diabetes Mellitus, Type 2

  • NCT07539415Phase 1Recruiting72 enrolled2026

    A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

    Daewoong Pharmaceutical Co. LTD.

    Obesity & Overweight · Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07179120Phase 2Not Yet Recruiting180 enrolled2026

    Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

    First Affiliated Hospital of Wenzhou Medical University

    Obesity-related Male Infertility

  • NCT07487103Phase 3Not Yet Recruiting478 enrolled2026

    Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

    Qilu Pharmaceutical Co., Ltd.

    Type 2 Diabetes

  • NCT07633639Recruiting200 enrolled2026

    GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

    China-Japan Friendship Hospital

    Obesity

  • NCT07588984Not Yet Recruiting2,310 enrolled2026

    GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

    Noom Inc.

    Obesity & Overweight · Weight Loss · Preventative Health · Body Weight

  • NCT07547878Phase 4Not Yet Recruiting64 enrolled2026

    Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    Baylor Research Institute

    Chronic Kidney Disease · Type 2 Diabetes

  • NCT07523633Phase 2Recruiting100 enrolled2026

    Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

    Anders Fink-Jensen, MD, DMSci

    Cannabis Use Disorder · Cannabis Use Disorders · Cannabis Abuse · Cannabis Dependence

  • NCT07599046Not Yet Recruiting20 enrolled2026

    Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes

    Eighth Affiliated Hospital, Sun Yat-sen University

    Obesity Type 2 Diabetes Mellitus

  • NCT07502508Phase 2Recruiting60 enrolled2026

    Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

    Biomea Fusion Inc.

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-523260-20-00Ongoing165 enrolled2026

    NN9662-8160

    Novo Nordisk A/S

    type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07581145Phase 3Recruiting52 enrolled2026

    Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

    Ole Lander Svendsen

    Foot Ulcer Due to Type 2 Diabetes Mellitus

  • 2023-504913-65-01Ongoing100 enrolled2026

    CODIF-015

    Bispebjerg Hospital

    Type 2 diabetes, Diabetic foot ulcer

  • NCT07653412Recruiting220 enrolled2026

    Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

    National and Kapodistrian University of Athens

    Obesity (Disorder) · Anti-obesity Agents · Precision Medicine

  • NCT07221214Phase 2Recruiting200 enrolled2026

    GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

    Vanderbilt University Medical Center

    HIV · Alcohol · Smoking Cigarette · Cardiovascular Disease Prevention

  • NCT07415954Phase 2Recruiting270 enrolled2026

    A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07527195Phase 1Recruiting100 enrolled2026

    Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

    Novo Nordisk A/S

    Obesity

  • NCT07107334Phase 2Recruiting20 enrolled2026

    A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

    University of Florida

    Endometrioid Endometrial Adenocarcinoma

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07554417Phase 4Not Yet Recruiting20 enrolled2026

    Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

    William Marsh Rice University

    GLP - 1 · Obesity & Overweight · Muscle Loss · Exercise Intervention

  • NCT07466017Phase 2Active Not Recruiting130 enrolled2026

    A Study of CS060380 Tablets in Patients With MASH and Obesity

    Cascade Pharmaceuticals, Inc

    Metabolic Dysfunction-associated Steatohepatitis (MASH) · Obesity

  • NCT07090343Phase 3Not Yet Recruiting826 enrolled2026

    Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

    Leiden University Medical Center

    Aortic Stenosis · Heart Failure

  • NCT07558863Phase 4Recruiting60 enrolled2026

    Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

    The First Affiliated Hospital with Nanjing Medical University

    Type 2 Diabetes · Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07589322Recruiting120 enrolled2026

    Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs

    Tri-Service General Hospital (TSGH)

    Obesity and Metabolic Syndrome

  • NCT07446998Phase 2Recruiting200 enrolled2026

    Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

    Veru Inc.

    Obesity & Overweight · Mobility Disability · HOMA-IR

  • NCT07505303Phase 2Active Not Recruiting151 enrolled2026

    MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

    Eccogene

    Adult Obesity · Weight Management

  • NCT07275697Phase 4Recruiting200 enrolled2026

    Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study

    Emma Svennberg

    Atrial Fibrillation (AF) · Obesity & Overweight

  • NCT07317115Recruiting20 enrolled2026

    Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

    GT Metabolic Solutions, Inc.

    Obesity (Disorder) · Obesity & Overweight · Type 2 Diabetes (T2DM)

  • NCT07223983Phase 1Recruiting10 enrolled2026

    Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

    Yale University

    Alcohol Use Disorder · Weight Loss · Bariatric Surgery Patients

  • NCT07361874Recruiting75 enrolled2026

    IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

    University of Texas Southwestern Medical Center

    Mild Autonomous Cortisol Secretion (MACS) · Autonomous Cortisol Secretion (ACS) · Subclinical Cushing's · Mild Autonomous Cortisol Excess

  • 2025-522970-35-00Ongoing158 enrolled2026

    REVERsal to normoglycemia by Treating PREDIABETES: the REVERT-PREDIABETES trial

    Region Midtjylland

    Coronary artery disease, Prediabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07465965Phase 1Recruiting60 enrolled2026

    A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

    Shanghai World Leader Pharmaceutical Co., Ltd.

    Overweight · Obesity

  • NCT07483801Phase 4Not Yet Recruiting112 enrolled2026

    DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

    Cambridge University Hospitals NHS Foundation Trust

    Cardiovascular Diseases

  • NCT07424430Not Yet Recruiting400 enrolled2026

    Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

    LMC Diabetes & Endocrinology Ltd.

    Diabetes (DM) · Type 2 Diabetes · Obesity (Disorder)

  • NCT06975111Phase 2/3Recruiting200 enrolled2026

    Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    University of Colorado, Denver

    Menopause · Menopause Hot Flashes · Menopause Related Conditions · Cardiovascular

  • NCT07605572Recruiting100 enrolled2026

    Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

    Attikon Hospital

    Dry Eye Disease (DED) · Diabete Mellitus · GLP-1 · Ocular Surface

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07204249Phase 2Recruiting162 enrolled2026

    Glutide for Ending Methamphetamine

    San Francisco Department of Public Health

    Methamphetamine-dependence

  • NCT07187830Recruiting52 enrolled2026

    Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

    University of Alberta

    Chronic Kidney Disease in Type 2 Diabetes · Obesity & Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07059377Phase 3Recruiting100 enrolled2026

    Semaglutide for Smoking Cessation in Patients With Diabetes

    Ottawa Heart Institute Research Corporation

    Diabetes Mellitus, Type 2 · Nicotine Addiction · Tobacco Dependence

  • NCT07456774Enrolling By Invitation100,000 enrolled2026

    A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

    Novo Nordisk A/S

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07325500Phase 2Recruiting30 enrolled2026

    Incretin Microdosing for Cardiometabolic Health in People With HIV

    The University of Texas Health Science Center, Houston

    Weight Gain

  • NCT07619508Completed100,000 enrolled2026

    Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.

    Brigham and Women's Hospital

    Obesity · Overweight

  • NCT07195994Recruiting90 enrolled2026

    A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

    QuickSilver Scientific

    Prediabetes / Type 2 Diabetes

  • NCT05689372Enrolling By Invitation600 enrolled2026

    Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07323134Not Yet Recruiting40 enrolled2026

    The Effect of Semaglutide on the Intestinal Flora in Obesity

    Beijing Chao Yang Hospital

    Obesity

  • NCT07391267Not Yet Recruiting90 enrolled2026

    Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

    Institute of Liver and Biliary Sciences, India

    Chronic Kidney Diseases · MAFLD

  • NCT06222437Phase 1Withdrawn2026

    Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

    Methodist Health System

    Polycystic Ovary Syndrome

  • NCT07294950Phase 3Recruiting98 enrolled2026

    Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

    Mount Sinai Hospital, Canada

    Obesity (Disorder) · Weight Change · Blood Pressure Monitoring · Appetite Regulation

  • NCT07382388Not Yet Recruiting70 enrolled2026

    A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis

    Peking University Third Hospital

    Psoriasis

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07417618Completed60,000 enrolled2026

    INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

    Brigham and Women's Hospital

    Type 2 Diabetes · Overweight · ASCVD

  • NCT07390110Active Not Recruiting25,664 enrolled2026

    Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

    Brigham and Women's Hospital

    Type 2 Diabetes · Heart Failure

  • NCT07297238Completed20 enrolled2026

    Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

    Jinling Hospital, China

    Short Bowel Syndrome (SBS) · Intestinal Failure

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07779343Recruiting300 enrolled2026

    OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme

    University of Health Sciences, Algeria

    Obesity Difficult Airway Airway Management · Obesity Adult Onset · Obesity and Cardiovascular Risk · Obesity Type 2 Diabetes Mellitus

  • NCT07619495Completed120,000 enrolled2026

    Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

    Brigham and Women's Hospital

    Type 2 Diabetes Mellitus · Obesity · Overweight

  • NCT07213466Phase 4Recruiting100 enrolled2026

    Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    Mayo Clinic

    Bipolar I Disorder · Bipolar II Disorder · Schizo Affective Disorder · Obesity

  • NCT07242534Phase 4Recruiting62 enrolled2026

    Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.

    Fundacion Dexeus

    Infertility · Obesity

  • 2025-522525-34-00Ongoing62 enrolled2026

    Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial

    Santiago Dexeus Font Fundacio Privada

    Infertility

  • NCT07040592Phase 2Recruiting30 enrolled2026

    Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

    Yale University

    Alcohol Use Disorder (AUD) · HIV

  • NCT07401992Phase 4Recruiting62 enrolled2026

    Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

    Hospital Universitario Dr. Jose E. Gonzalez

    Psoriasis (PsO) · Obesity & Overweight · Diabetes Mellitus - Type 2

  • NCT07227948Phase 2Recruiting75 enrolled2026

    Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

    The University of Texas Health Science Center, Houston

    Cocaine Use Disorder

  • NCT07253285Phase 3Recruiting460 enrolled2026

    A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT07172867Phase 2Withdrawn2026

    A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

    Halia Therapeutics, Inc.

    Diabetes Mellitus, Type 2 · Obesity

  • NCT06913023Phase 2/3Not Yet Recruiting74 enrolled2026

    Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

    University Health Network, Toronto

    Kidney Transplant Recipient

  • NCT07135245Phase 2Not Yet Recruiting180 enrolled2026

    Improved Treatment and Monitoring of Alzheimer's Disease

    Rune Skovgaard Rasmussen

    Alzheimer Disease (AD)

  • NCT07640139Enrolling By Invitation125,000 enrolled2026

    Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

    Indiana University

    Obesity

  • NCT07187856Phase 2Not Yet Recruiting80 enrolled2026

    Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

    ProGen. Co., Ltd.

    Type 2 Diabetes Mellitus (T2DM)

  • NCT05714683Not Yet Recruiting600 enrolled2025

    Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07284979Phase 3Recruiting1,200 enrolled2025

    Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

    Kailera

    Obesity

  • NCT07297589Phase 3Recruiting136 enrolled2025

    Epicardial Cardiac Fat-CT (EPIC-CT)

    Instituto Mexicano del Seguro Social

    STEMI - ST Elevation Myocardial Infarction · Epicardial Fat

  • NCT07295223Phase 3Recruiting44 enrolled2025

    Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

    Instituto Mexicano del Seguro Social

    Acute Myocardial Infarction With ST Elevation

  • NCT07319975Not Yet Recruiting48 enrolled2025

    Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

    Istanbul Galata University

    Obesity

  • NCT07285902Phase 3Active Not Recruiting572 enrolled2025

    A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

    Fujian Shengdi Pharmaceutical Co., Ltd.

    Obesity

  • NCT07058155Phase 4Recruiting70 enrolled2025

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    The Cleveland Clinic

    Liver Cirrhoses · Portal Hypertension Related to Cirrhosis · Severe Obesity · TIPS

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07276763Not Yet Recruiting16,509 enrolled2025

    Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

    Fudan University

    Gastric Retention

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07271251Phase 3Completed267 enrolled2025

    A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

    Novo Nordisk A/S

    Type 2 Diabetes

  • NCT07251556Phase 4Not Yet Recruiting40 enrolled2025

    GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

    Chinese University of Hong Kong

    Psoriasis Arthritis

  • NCT07302802Recruiting70 enrolled2025

    Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

    Prof. Dr. Martin Wabitsch

    Monogenic Obesity

  • NCT07229170Recruiting150 enrolled2025

    Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

    San Raffaele Telematic University

    Obesity & Overweight · Taste Alterations · Weight Loss · Eating Behavior Changes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07017270Phase 4Recruiting100 enrolled2025

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Unity Health Toronto

    Kidney Disease, Chronic · Diabetes · Dialysis · End Stage Kidney Disease (ESRD)

  • NCT06954090Phase 4Enrolling By Invitation50 enrolled2025

    Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

    Steno Diabetes Center Copenhagen

    Type 2 DM · Type 2 DM /Diabetic Nephropathy · Albuminuria

  • NCT07178145Phase 4Recruiting192 enrolled2025

    Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

    University of Virginia

    Heart Failure Preserved Ejection Fraction · Epicardial Adipose Tissue

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-521748-39-00Temporarily Halted80 enrolled2025

    SHICAN

    Universita Cattolica Del Sacro Cuore

    type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07280221Enrolling By Invitation500 enrolled2025

    WEgovy Real World Assessment of Weight Loss in Korea

    Novo Nordisk A/S

    Obesity

  • NCT07225816Phase 1Recruiting71 enrolled2025

    Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

    Novo Nordisk A/S

    Obesity

  • NCT07202247Phase 2Recruiting60 enrolled2025

    Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

    City of Hope Medical Center

    Prostate Carcinoma · Recurrent Prostate Carcinoma

  • 2025-522503-18-00Ongoing160 enrolled2025

    SAFE-K

    Region Midtjylland

    Chronic kidney disease

  • 2024-518682-95-00Ongoing36 enrolled2025

    SIGNAL - Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes

    Steno Diabetes Center Copenhagen

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-518086-99-00Revoked255 enrolled2025

    2019-002274-31

    Kobenhavns Universitet

    Obesity

  • NCT06909006Phase 3Not Yet Recruiting122 enrolled2025

    Semaglutide Treatment in Type 1 Diabetes

    Nordsjaellands Hospital

    Obesity in Diabetes · Obesity/Therapy · Type 1 Diabetes Mellitus (T1DM) · Insulin Sensitivity/Resistance

  • NCT07073053Phase 4Not Yet Recruiting60 enrolled2025

    The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

    Taipei Veterans General Hospital, Taiwan

    Glucagon-Like Peptide-1 Receptor Agonists · Type 2 Diabetes · Coronary Arterial Disease (CAD)

  • NCT06801015Phase 4Active Not Recruiting30 enrolled2025

    Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

    Mayo Clinic

    Obesity

  • NCT07156331Not Yet Recruiting20 enrolled2025

    Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes

    Kristin Clemens

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-520322-11-00Temporarily Halted74 enrolled2025

    BP45703

    F. Hoffmann-La Roche AG

    Type 2 Diabetes Mellitus (T2D)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07200622Phase 2Not Yet Recruiting60 enrolled2025

    Oral Semaglutide in Patients With Alzheimer's Disease

    Imperial College London

    Alzheimer Disease

  • NCT07150975Phase 3Recruiting420 enrolled2025

    Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

    Gan & Lee Pharmaceuticals.

    Obesity/Overweight in Adult

  • NCT07216651Completed20 enrolled2025

    WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

    Closed Loop Medicine

    Obesity & Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07165158Phase 4Not Yet Recruiting150 enrolled2025

    The Effect of Semaglutide on Bone Health

    The First Affiliated Hospital of Xiamen University

    Osteoporosis · Osteoporosis Fracture · T2DM

  • NCT07152756Not Yet Recruiting418 enrolled2025

    Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

    Fudan University

    Gastric Retention

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07156591Not Yet Recruiting460 enrolled2025

    Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention

    Fudan University

    Gastric Retention

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07136714Phase 4Recruiting116 enrolled2025

    Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

    Nordsjaellands Hospital

    Major Depressive Disorder

  • NCT07169136Recruiting20 enrolled2025

    Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

    Nemours Children's Clinic

    Polycystic Ovarian Syndrome in Adolescent Females · Obesity (Disorder)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07314684Phase 4Recruiting80 enrolled2025

    GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

    Federico II University

    T2DM (Type 2 Diabetes Mellitus)

  • NCT07171723Phase 1/2Recruiting24 enrolled2025

    Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment

    University Hospital, Gentofte, Copenhagen

    Obesity &Amp; Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06807970Early Phase 1Active Not Recruiting54 enrolled2025

    Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist

    The University of Hong Kong

    Osteoarthritis (OA) of the Knee

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07139548Phase 3Not Yet Recruiting600 enrolled2025

    A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

    Guangdong Raynovent Biotech Co., Ltd

    T2DM

  • NCT07112872Phase 2Active Not Recruiting240 enrolled2025

    A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus

  • NCT07091500Recruiting40 enrolled2025

    Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

    Washington University School of Medicine

    Obesity · Skeletal Muscle · Brain Connectivity

  • NCT07115069Active Not Recruiting60 enrolled2025

    Comparison of Body Composition Changes With Weight Loss Interventions

    Vanderbilt University Medical Center

    Obesity

  • NCT07081178Terminated100 enrolled2025

    A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

    Novo Nordisk A/S

    Obesity

  • NCT06691243Phase 2Recruiting40 enrolled2025

    Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

    University of Maryland, Baltimore

    Cocaine Use Disorder · HIV

  • 2024-520328-27-00Ongoing59 enrolled2025

    J1R-MC-GZFD

    Eli Lilly & Co.

    Type 2 Diabetes

  • NCT06885736Recruiting232 enrolled2025

    LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy

    Dasman Diabetes Institute

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07621419Recruiting145 enrolled2025

    Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin

    Hospital Italiano de Buenos Aires

    Diabetes Mellitus

  • NCT07065383Recruiting60 enrolled2025

    Rebalancing the Fat Content of the Heart and Muscles

    University of Aberdeen

    Diabetes Mellitus Type 2

  • NCT07046273Phase 3Not Yet Recruiting496 enrolled2025

    Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

    Shandong New Time Pharmaceutical Co., LTD

    Type 2 Diabetes (T2DM)

  • NCT07513168Phase 4Recruiting60 enrolled2025

    Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

    Asian Institute Of Medical Sciences

    Obesity · Weight Reduction · Cardiometabolic Risk Factors

  • NCT07073417Phase 2Active Not Recruiting163 enrolled2025

    A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

    Hangzhou Sciwind Biosciences Co., Ltd.

    Obesity · Weight Management

  • NCT07254572Phase 4Recruiting300 enrolled2025

    Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

    National Institute of Cardiology, Warsaw, Poland

    Coronary Artery Disease · PreDiabetes

  • 2023-508525-27-00Ongoing300 enrolled2025

    CSDS.IV/VIII/2023

    Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

    Coronary Heart Disease, Prediabetes, Coronary Atherosclerosis, Coronary Artery Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-516542-19-00Ongoing148 enrolled2025

    BioPhenoT2D

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07064486Phase 3Recruiting477 enrolled2025

    A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

    BrightGene Bio-Medical Technology Co., Ltd.

    Type 2 Diabetes (T2DM)

  • NCT06908694Phase 4Recruiting20 enrolled2025

    Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

    Hamilton Health Sciences Corporation

    Prostate Cancer

  • NCT07087795Phase 1Active Not Recruiting96 enrolled2025

    A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 1

  • NCT07030621Phase 3Not Yet Recruiting436 enrolled2025

    Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

    RenJi Hospital

    Acute Ischemic Stroke

  • NCT07041983Enrolling By Invitation30 enrolled2025

    24-h Energy Expenditure and Anti-obesity Medication

    University of Pisa

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-519533-38-00Revoked96 enrolled2025

    NN6497-8316

    Novo Nordisk A/S

    Diabetes mellitus type 1

  • 2024-517471-21-02Ongoing34 enrolled2025

    The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study

    Clinical Pharmacology, Department of

    Adipositas

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07101939Phase 2Recruiting120 enrolled2025

    A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

    Actimed Therapeutics Ltd

    Obesity · Muscle Loss

  • NCT06924697Enrolling By Invitation46 enrolled2025

    Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients

    Shanghai East Hospital

    Diabetes Mellitus, Type 2 · Nicotine Dependence, Cigarettes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07239570Phase 4Recruiting125 enrolled2025

    A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

    Peter Rossing

    Chronic Kidney Disease(CKD)

  • NCT06852391Phase 4Recruiting74 enrolled2025

    JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

    McMaster University

    Obesity (Disorder)

  • NCT07010432Phase 1Recruiting144 enrolled2025

    The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    Novo Nordisk A/S

    Obesity

  • NCT06967389Recruiting50 enrolled2025

    Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

    John Bauer

    Obesity and Overweight · Obese Adolescents · Weight Management · Weight Loss

  • NCT06989177Recruiting140 enrolled2025

    Probiotic Intervention on Body Weight

    Chinese Academy of Sciences

    Obesity · Homeostasis · Weight Loss · Probiotic Intervention

  • NCT06989203Recruiting140 enrolled2025

    Protein Supplementation Intervention on Body Weight

    Chinese Academy of Sciences

    Obesity · Weight Loss · Protein Supplementation

  • NCT07610174Phase 2Completed160 enrolled2025

    Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves

    Kafrelsheikh University

    Heart Failure · Heart Valve Prosthesis

  • NCT07293325Recruiting66 enrolled2025

    Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

    Second Affiliated Hospital, Zhejiang University, School of Medicine

    Adults With Simple Obesity

  • NCT06982859Phase 1Active Not Recruiting95 enrolled2025

    A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

    Eli Lilly and Company

    Diabetes Mellitus · Insulin Sensitivity

  • NCT06639464Phase 2Recruiting46 enrolled2025

    Semaglutide for Helping Opioid Recovery

    Brigham and Women's Hospital

    Opioid Use Disorder

  • NCT07374328Phase 1/2Recruiting240 enrolled2025

    Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

    Second Affiliated Hospital of Guangzhou Medical University

    Type 2 Diabetes

  • NCT06946628Phase 3Not Yet Recruiting296 enrolled2025

    New Triple Therapy in Newly Diagnosed Type 2 Diabetes

    Sun Yat-sen University

    Diabetes Mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06851962Phase 4Active Not Recruiting504 enrolled2025

    Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

    Fundación para la Investigación del Hospital Clínico de Valencia

    Diabetes Mellitus Type 2

  • 2024-511734-13-04Ongoing120 enrolled2025

    Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.

    Region Hovedstaden

    Unipolar depression Overweight and obesity, Obesity and overweight

  • 2025-520686-46-00Revoked504 enrolled2025

    EPHIC-DIA2

    Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

    Type 2 Diabetes Mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06497595Recruiting60 enrolled2025

    Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

    Sheba Medical Center

    Type 2 Diabetes Mellitus in Obese

  • NCT06884293Phase 3Active Not Recruiting479 enrolled2025

    A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

    Innovent Biologics (Suzhou) Co. Ltd.

    Overweight · Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

  • NCT07057310Phase 4Enrolling By Invitation30 enrolled2025

    Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

    Mayo Clinic

    Obesity · Menopause

  • NCT07055607Enrolling By Invitation1,250 enrolled2025

    A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

    Novo Nordisk A/S

    Obesity

  • 2024-513958-29-00Temporarily Halted50 enrolled2025

    TRI CRF 23-05

    Trinity College Dublin

    Cardiovascular disorders: Hypertension and Obesity

  • NCT06972992Phase 1Completed28 enrolled2025

    A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

    Ascletis Pharma (China) Co., Limited

    Chronic Weight Management

  • NCT06499857Phase 3Recruiting200 enrolled2025

    Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

    University of Chicago

    Overweight or Obesity · Atrial Fibrillation

  • 2024-510846-15-00Temporarily Halted120 enrolled2025

    NN9541-7841

    Novo Nordisk A/S

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

  • NCT06706284Phase 4Recruiting50 enrolled2025

    Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

    Marzieh Salehi

    Spinal Cord Injuries · Type 2 Diabetes

  • 2024-518510-87-00Ongoing126 enrolled2025

    Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON)

    Rigshospitalet

    Glaucoma

  • NCT06619015Phase 2/3Withdrawn2025

    Tailoring Obesity Treatment Trial

    Esbjerg Hospital - University Hospital of Southern Denmark

    Obesity · Appetite Regulation · PreDiabetes

  • NCT06894784Phase 3Recruiting36 enrolled2025

    A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

    McGill University Health Centre/Research Institute of the McGill University Health Centre

    Diabetes Type 1

  • NCT06745284Phase 1Active Not Recruiting64 enrolled2025

    A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

    Boehringer Ingelheim

    Obesity

  • NCT07163624Phase 2Completed211 enrolled2025

    UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

    The United Bio-Technology (Hengqin) Co., Ltd.

    Type 2 Diabetes Mellitus (T2DM)

  • NCT06937060Phase 3Recruiting14 enrolled2025

    Effect of Semaglutide in Patients With Psoriasis and Obesity

    The University of Hong Kong

    Psoriasis (PsO) · Obesity and Overweight

  • NCT06856291Recruiting40 enrolled2025

    Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance

    ETH Zurich

    Obesity and Obesity-related Medical Conditions · Obesity and Overweight · Insulin Sensitivity/Resistance · Semaglutide

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05829460Phase 2Withdrawn2025

    Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

    Washington University School of Medicine

    Endometrial Hyperplasia

  • 2022-502164-20-01Ongoing152 enrolled2025

    NOK0024 / Z2023097

    Stichting Zuyderland Medisch Centrum

    obesity

  • NCT05646199Phase 2/3Unknown60 enrolled2025

    Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

    University of Hull

    Polycystic Ovary Syndrome

  • NCT06738979Phase 3Not Yet Recruiting408 enrolled2025

    A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    Obesity

  • NCT06856928Not Yet Recruiting16 enrolled2025

    Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

    University of Colorado, Denver

    Obesity; Drug

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2023-506289-29-00Ongoing220 enrolled2025

    eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity)

    Vestfold Hospital Trust

    Obesity

  • NCT06830343Phase 1Recruiting66 enrolled2025

    The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

    CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

    Overweight or Obesity

  • 2024-512562-34-00Revoked118 enrolled2025

    D7261C00001

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06814938Phase 4Active Not Recruiting135 enrolled2025

    A Study of a Novel Precision Medicine Approach For Obesity

    Mayo Clinic

    Obesity

  • NCT06825793Not Yet Recruiting56 enrolled2025

    Semaglutide's Weight Loss Effects in Obesity

    Beijing Chao Yang Hospital

    Obesity

  • NCT06715514Active Not Recruiting96 enrolled2025

    Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

    Lia Bally

    Menopause · Type 2 Diabetes

  • 2023-508055-40-00Temporarily Halted309 enrolled2025

    NN9536-7752

    Novo Nordisk A/S

    Obesity

  • NCT07223242Phase 2/3Recruiting120 enrolled2025

    Tailored Exercise Training Study Among Adults With HFpEF

    University of Texas Southwestern Medical Center

    HFpEF - Heart Failure With Preserved Ejection Fraction · Diabetic Cardiomyopathies

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06778967Phase 3Active Not Recruiting1,100 enrolled2025

    A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

    Gan & Lee Pharmaceuticals.

    Type 2 Diabetes Mellitus (T2DM)

  • 2023-506434-69-00Temporarily Halted36 enrolled2025

    17456

    Universitair Medisch Centrum Groningen

    Chronic Kidney Disease

  • NCT06780449Phase 3Active Not Recruiting400 enrolled2025

    A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

    Novo Nordisk A/S

    Obesity

  • NCT06788626Phase 3Not Yet Recruiting390 enrolled2025

    Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

    Wei Hu

    Acute Ischemic Stroke · Large Vessel Occlusion · Neuroprotective Drugs · Endovascular Treatment

  • NCT06896981Phase 2/3Recruiting30 enrolled2025

    Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

    Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    Polycystic Ovary Syndrome (PCOS) Women · Obesity

  • NCT06790160Recruiting100 enrolled2025

    Study of Patients Being Treated With Anti-obesity Medication

    Texas Tech University

    Obesity and Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06803888Phase 4Active Not Recruiting125 enrolled2025

    Bariatric Surgery vs. Semaglutide vs. Tirzepatide

    Ali Aminian

    Obesity and Obesity-related Medical Conditions

  • NCT06762314Phase 2Recruiting105 enrolled2025

    Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

    Mostafa Bahaa

    Diabetes

  • NCT06608433Completed22 enrolled2025

    Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

    University Hospital, Basel, Switzerland

    Healthy Volunteer Study · HPA · Cortisol Deficiency · Adrenal Insufficiency

  • NCT06914102Completed58,387 enrolled2025

    Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2 · HFpEF - Heart Failure With Preserved Ejection Fraction

  • NCT06914141Completed28,118 enrolled2025

    Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2 · HFpEF - Heart Failure With Preserved Ejection Fraction

  • NCT06548490Phase 2Recruiting200 enrolled2025

    GLP-1R Agonist Treatment for Opioid Use Disorder

    Milton S. Hershey Medical Center

    Opioid Use Disorder · Opioid Abuse and Addiction · Narcotic-Related Disorders · Substance-Related Disorders

  • NCT06771115Phase 2Completed176 enrolled2025

    Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

    Zomagen Biosciences Ltd.

    Obesity

  • NCT07190144Completed122 enrolled2025

    Coronary Flow Reserve Changes After Semaglutide Treatment

    Ekrem Bilal Karaayvaz

    The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients · Obesity &Amp; Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07036172Phase 3Recruiting460 enrolled2025

    Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    Obesity Control

  • NCT07740291Recruiting27 enrolled2025

    Tirzepatide Impact Assessment Study

    Texas Tech University

    Obesity & Overweight · Cardiometabolic Health Indicators · Addiction · Eating Disorders

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06754163Phase 4Active Not Recruiting20 enrolled2025

    Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

    St Andrew's Healthcare

    Obesity and Obesity-related Medical Conditions · Psychiatric Disorders

  • NCT06764056Not Yet Recruiting120 enrolled2025

    Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

    Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

    Metabolic Associated Fatty Liver Disease · Metabolic Associated-dysfunction Steatohepatitis (MASH) · Obesity

  • NCT06792422Phase 4Recruiting126 enrolled2025

    A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

    Glostrup University Hospital, Copenhagen

    Primary Open Angle Glaucoma (POAG) · Open-Angle Glaucoma · Glaucoma

  • NCT06980623Active Not Recruiting26,000 enrolled2025

    Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

    Brigham and Women's Hospital

    Type 2 Diabetes · Heart Failure

  • NCT07281196Completed15 enrolled2025

    Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

    Shanghai Fengxian District Central Hospital

    Sleep Apnea Syndrome (OSAS)

  • NCT07732738Recruiting400 enrolled2025

    Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

    China-Japan Friendship Hospital

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07325435Phase 4Active Not Recruiting60 enrolled2024

    Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

    MaryAnn Banerji

    Type 2 Diabetes (T2DM)

  • NCT05670379Phase 1Completed24 enrolled2024

    Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

    Vivani Medical, Inc

    Overweight and Obesity · Type2diabetes

  • 2024-518040-21-00Revoked80 enrolled2024

    HS-24-787

    Camurus AB

    Body weight management

  • NCT07092618Phase 2/3Recruiting150 enrolled2024

    Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

    AgelessRx

    Longevity · GLP-1 · Geroscience · Aging

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06874751Completed45,456 enrolled2024

    Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

    Novo Nordisk A/S

    Overweight · Obesity · Atherosclerotic Cardiovascular Disease (ASCVD)

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06648031Phase 1Completed148 enrolled2024

    Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

    Lexaria Bioscience Corp.

    Type2diabetes

  • NCT06717698Phase 2Recruiting465 enrolled2024

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

    Novo Nordisk A/S

    Chronic Kidney Disease

  • NCT06387199Phase 2/3Recruiting26 enrolled2024

    Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

    McGill University Health Centre/Research Institute of the McGill University Health Centre

    Type 1 Diabetes · Diabetes Mellitus

  • NCT06716216Phase 3Recruiting537 enrolled2024

    A Study of BGM0504 in Participants with Type 2 Diabetes

    BrightGene Bio-Medical Technology Co., Ltd.

    Type 2 Diabetes Mellitus (T2DM)

  • NCT07018544Enrolling By Invitation840 enrolled2024

    A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

    Novo Nordisk A/S

    Obesity and Overweight

  • NCT06761703Completed200 enrolled2024

    A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss

    Amgen

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06534411Phase 3Completed1,023 enrolled2024

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07092605Early Phase 1Enrolling By Invitation150 enrolled2024

    Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

    AgelessRx

    Longevity · Quality of Life · Mood · Inflammation

  • NCT06779929Completed70,000 enrolled2024

    Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    Brigham and Women's Hospital

    Type 2 Diabetes

  • NCT06616961Phase 3Not Yet Recruiting480 enrolled2024

    Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

    Popular Medical College Hospital

    Obesity · Type 2 Diabetes Mellitus (T2DM)

  • NCT06467604Active Not Recruiting7 enrolled2024

    CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

    University of California, Davis

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06649344Phase 3Completed884 enrolled2024

    A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

    Fujian Shengdi Pharmaceutical Co., Ltd.

    Type 2 Diabetes

  • NCT06633783Phase 3Not Yet Recruiting370 enrolled2024

    A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

    Hangzhou Jiuyuan Gene Engineering Co. Ltd.,

    Obesity

  • NCT06659744Completed158,310 enrolled2024

    Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2

  • NCT06659718Completed43,650 enrolled2024

    Emulation of the SOUL Diabetes Trial in Healthcare Claims

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2

  • NCT06659679Completed26,126 enrolled2024

    Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2

  • 2023-506109-20-00Ongoing140 enrolled2024

    STABIL-NOR study

    Helse Bergen HF

    Metabolic control in antipsychotic-using patients

  • NCT06642584Phase 1Completed90 enrolled2024

    A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

  • 2024-514906-30-00Ongoing76 enrolled2024

    TOLEDDO

    Centre Hospitalier Universitaire De Dijon

    "double diabetes"

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06575738Phase 1Recruiting40 enrolled2024

    Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

    University of Colorado, Denver

    Obesity · Adolescent Obesity · Body-Weight Trajectory · Weight Loss Trajectory

  • NCT06500143Completed94 enrolled2024

    Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

    Ciusss de L'Est de l'Île de Montréal

    Gastric Retention

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06579105Phase 2Completed406 enrolled2024

    Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

    AstraZeneca

    Diabetes Mellitus, Type 2

  • NCT06613854Phase 4Recruiting90 enrolled2024

    Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

    University Medical Centre Ljubljana

    Type 2 Diabetes Mellitus (T2DM)

  • NCT07096063Completed887,132 enrolled2024

    Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

    Brigham and Women's Hospital

    Type 2 Diabetes · Overweight · Cardiovascular (CV) Risk

  • NCT05202353Phase 1Active Not Recruiting29 enrolled2024

    A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

    Boehringer Ingelheim

    Obesity

  • 2024-515417-17-00Temporarily Halted30 enrolled2024

    14040047

    Boehringer Ingelheim International GmbH

    No targeted indication. Male and female subjects with obesity.

  • NCT06269120Completed243 enrolled2024

    SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

    Novo Nordisk A/S

    Type 2 Diabetes

  • NCT06396416Phase 4Recruiting60 enrolled2024

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Western University, Canada

    Obesity · Chronic Kidney Disease

  • NCT06634927Phase 1Completed68 enrolled2024

    Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    Type 2 Diabetes

  • NCT06604624Phase 3Completed462 enrolled2024

    Semaglutide in Treatment of Obesity

    CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

    Weight Management

  • NCT05702931Phase 4Recruiting104 enrolled2024

    Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

    Rigshospitalet, Denmark

    Hyperglycemia · Renal Transplant Complication Primary Non-Function · Diabetes

  • NCT06571383Phase 4Active Not Recruiting500 enrolled2024

    STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

    Novo Nordisk A/S

    Obesity

  • NCT06446531Phase 1Recruiting64 enrolled2024

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    The University of Texas Health Science Center at San Antonio

    Pre-Diabetes · Weight, Body · Cardiovascular Diseases

  • 2022-502139-20-00Ongoing40 enrolled2024

    PROTECT

    Rigshospitalet

    Mucositis and systemical inflammation, which is a treatment-related complication after treatment with high-dose chemotherapy

  • NCT06507475Completed209 enrolled2024

    Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2023-504159-29-01Ongoing104 enrolled2024

    Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation

    Rigshospitalet

    Hyperglycaemia after renal transplantation

  • NCT06557811Phase 4Not Yet Recruiting88 enrolled2024

    Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

    University of Sao Paulo General Hospital

    Diabetic Patients · Acute Myocardial Infarction

  • NCT06577090Phase 2Active Not Recruiting136 enrolled2024

    Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

    Skye Bioscience, Inc.

    Obesity

  • NCT06449625Phase 2Not Yet Recruiting40 enrolled2024

    Semaglutide in Auto-HSCT

    Klaus Gottlob Müller

    Intestinal Mucositis · Inflammation · Chemotherapeutic Toxicity

  • NCT06555146Not Yet Recruiting15 enrolled2024

    Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

    Bispebjerg Hospital

    Diabetes Mellitus, Type 2 · Kidney Disease, Chronic

  • NCT06468748Phase 4Withdrawn2024

    The Effects of Semaglutide on Body Composition and Performance in Military Personnel

    United States Army Research Institute of Environmental Medicine

    Obesity

  • NCT06422624Phase 1Unknown14 enrolled2024

    A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

    Bostal Drug Delivery Co., Ltd

    Diabetes Mellitus, Type 2

  • NCT06533527Phase 4Completed69 enrolled2024

    Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

    The Cleveland Clinic

    Diabetes Mellitus, Type 2 · Obesity · Gastroparesis

  • 2022-501392-81-00Temporarily Halted280 enrolled2024

    2022-501392-81-00

    Stichting Rijnstate Ziekenhuis

    Atrial fibrillation, Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06184633Phase 4Recruiting280 enrolled2024

    DUTCH Weight Control in Atrial Fibrillation Study

    Rijnstate Hospital

    Atrial Fibrillation · Obesity · Weight Loss

  • NCT06492330Completed62 enrolled2024

    Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

    Shanghai Jiao Tong University School of Medicine

    Metabolic Dysfunction-Associated Steatohepatitis (MASH) · Obesity · Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06411210Phase 2Recruiting54 enrolled2024

    Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

    Yale University

    Diabetes type1 · Obesity

  • NCT06541509Phase 1/2Unknown10 enrolled2024

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    University Medical Centre Ljubljana

    Heart Failure · Obesity

  • NCT06986993Phase 4Recruiting40 enrolled2024

    Impact of Semaglutide on Tobacco Use and Related Health Behaviors

    University of Oklahoma

    Tobacco Use

  • NCT06082063Phase 3Recruiting2,000 enrolled2024

    Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

    Steno Diabetes Center Copenhagen

    Cardiovascular Diseases · Heart Failure · Type 1 Diabetes · Kidney Failure

  • NCT06487832Recruiting60 enrolled2024

    Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

    University Hospital Tuebingen

    Normal Weight · Overweight and Obesity · Insulin Sensitivity · Insulin Resistance

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06478550Completed304 enrolled2024

    A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06388187Phase 3Completed300 enrolled2024

    A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Obesity

  • NCT06500429Phase 2Completed120 enrolled2024

    A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

    Neurogastrx, Inc.

    Overweight and Obesity · Healthy

  • NCT06461377Phase 4Recruiting50 enrolled2024

    The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy

    The First Affiliated Hospital with Nanjing Medical University

    Type 2 Diabetes · Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)

  • NCT06338553Early Phase 1Recruiting24 enrolled2024

    GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

    Vanderbilt University Medical Center

    Type 1 Diabetes

  • NCT06283667Active Not Recruiting1,071 enrolled2024

    Special Use - Results Surveillance on Long-term Use With Wegovy®

    Novo Nordisk A/S

    Obesity

  • NCT05897398Completed1,100 enrolled2024

    SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®

    Hospices Civils de Lyon

    Obesity · Bariatric Surgery · Binge Eating Disorder · Syndromic Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06050577Phase 2Active Not Recruiting64 enrolled2024

    The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

    Odense University Hospital

    Type 2 Diabetes · Osteopenia

  • NCT06363487Completed70 enrolled2024

    Semaglutide and Cognition in Healthy Volunteers

    University of Oxford

    Cognitive Change

  • NCT06409130Phase 2Completed270 enrolled2024

    Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

    Novo Nordisk A/S

    Alcohol-related Liver Disease

  • NCT06318442Recruiting60 enrolled2024

    The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes

    Imperial College London

    Steroid-Induced Diabetes · Steroid Induced Hyperglycemia

  • NCT06821919Recruiting70 enrolled2024

    Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

    Western Galilee Hospital-Nahariya

    Diabetes Mellitus · Kidney Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06403761Phase 1Completed158 enrolled2024

    Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06361823Phase 3Unknown74 enrolled2024

    Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

    Capital Medical University

    Idiopathic Intracranial Hypertension

  • NCT06287307Phase 4Not Yet Recruiting152 enrolled2024

    Semaglutide 2.4mg for Low Responders After Bariatric Surgery

    Zuyderland Medisch Centrum

    Obesity · Obesity, Morbid · Weight Gain

  • NCT06401746Recruiting15 enrolled2024

    Body Surface Gastric Mapping in Patients on Semaglutide

    University of Western Sydney

    Semaglutide-Induced Gastric Motility · Gastroparesis

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06423599Phase 2/3Recruiting100 enrolled2024

    Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

    Jens D Hove, MD,PHD

    Heart Failure With Reduced Ejection Fraction · Obesity · Weight Loss · Chronic Heart Failure

  • NCT06282458Phase 2Completed168 enrolled2024

    Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

    Veru Inc.

    Muscle Loss · Obesity

  • NCT06173778Phase 2Recruiting197 enrolled2024

    Semaglutide for Post-Smoking Cessation Weight Management

    The University of Texas Health Science Center, Houston

    Obesity · Overweight · Cigarette Smoking

  • NCT05822609Phase 2Recruiting60 enrolled2024

    Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

    University of Washington

    Diabetic Kidney Disease · Type 1 Diabetes

  • NCT06390501Completed60 enrolled2024

    The Effect of Weekly Semaglutide Treatment on Energy Expenditure

    Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences

    Obesity; Drug

  • NCT06131372Phase 2Completed626 enrolled2024

    A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

    Novo Nordisk A/S

    Chronic Kidney Disease · Type 2 Diabetes · Obesity

  • NCT06339086Phase 3Unknown478 enrolled2024

    Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

    Chengdu Brilliant Pharmaceutical Co., Ltd.

    Type 2 Diabetes Mellitus

  • NCT06323161Phase 3Completed274 enrolled2024

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

    Novo Nordisk A/S

    Type 2 Diabetes

  • 2023-503753-35-01Ongoing100 enrolled2024

    FIT-HF trial

    Region Hovedstaden

    Obesity and Heart Failure with reduced Ejection Fracition

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06323174Phase 3Completed189 enrolled2024

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

    Novo Nordisk A/S

    Type 2 Diabetes

  • NCT06271200Recruiting200 enrolled2024

    Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

    National Health Research Institutes, Taiwan

    Metabolic Syndrome

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06299098Phase 2Active Not Recruiting1,005 enrolled2024

    A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

    Regeneron Pharmaceuticals

    Obesity

  • NCT06003153Phase 4Recruiting125 enrolled2024

    GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

    Massachusetts General Hospital

    Genetic Predisposition · Metabolic Diseases · Type 2 Diabetes

  • NCT06410352Phase 4Recruiting220 enrolled2024

    Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

    University Medical Center, Kazakhstan

    Metabolic Syndrome

  • NCT06184568Phase 3Completed349 enrolled2024

    A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

    Innovent Biologics (Suzhou) Co. Ltd.

    Type 2 Diabetes · Obesity

  • NCT06149260Phase 1Unknown10 enrolled2024

    Subcutaneous Semaglutide in Systemic Scleroderma

    Second Xiangya Hospital of Central South University

    Scleroderma, Systemic · Fibrosis · Semaglutide

  • NCT06289504Phase 1Completed34 enrolled2024

    A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

    Novo Nordisk A/S

    Obesity

  • NCT06161844Phase 3Completed506 enrolled2024

    Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

    CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    Type 2 Diabetes Mellitus

  • NCT06207877Phase 1Completed62 enrolled2024

    A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

    Novo Nordisk A/S

    Obesity

  • NCT05424003Phase 2Recruiting50 enrolled2024

    Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

    University of Virginia

    NAFLD

  • NCT06260722Phase 3Active Not Recruiting1,250 enrolled2024

    Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

  • NCT06234111Active Not Recruiting35 enrolled2024

    Semaglutide and Physical Activity for Obesity and Multimorbidity

    Hvidovre University Hospital

    Obesity Morbid · Multimorbidity · Obesity

  • NCT06243536Phase 4Unknown60 enrolled2024

    The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

    University Hospital Sestre Milosrdnice

    Type 2 Diabetes · Overweight · Disordered Eating Behaviors

  • NCT06132477Phase 4Recruiting150 enrolled2024

    Impact GLP-1 Agonists Following Bariatric

    University of Missouri-Columbia

    Morbid Obesity · Metabolic Syndrome · Diabetes Mellitus · Hypertension

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06072963Phase 2Recruiting80 enrolled2024

    COMMETS- Combination MCI Metabolic Syndrome

    Rutgers, The State University of New Jersey

    Alzheimer Disease · Mild Cognitive Impairment · Metabolic Syndrome

  • NCT05746039Phase 1/2Recruiting8 enrolled2024

    Feasibility of Semaglutide in Advanced Lung Disease

    University of Pennsylvania

    Obesity · Interstitial Lung Disease · Chronic Obstructive Pulmonary Disease · Sarcoidosis, Pulmonary

  • NCT06083675Phase 3Withdrawn2024

    Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06699329Phase 1Completed38 enrolled2024

    A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

    Merck Sharp & Dohme LLC

    Healthy

  • NCT06221969Phase 3Completed1,024 enrolled2024

    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Novo Nordisk A/S

    Type 2 Diabetes

  • NCT05780905Phase 4Recruiting50 enrolled2024

    Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

    University of Washington

    Diabetes Mellitus, Type 2 · Stroke (CVA) or Transient Ischemic Attack

  • NCT05892432Phase 2Completed50 enrolled2024

    Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

    University of Colorado, Denver

    Alcohol Use Disorder

  • NCT06351748Completed34,238 enrolled2024

    Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06959784Phase 4Enrolling By Invitation142 enrolled2024

    Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

    China-Japan Friendship Hospital

    Diabetes Mellitus · Cardiovascular Diseases · Cerebrovascular Disease

  • NCT06057077Phase 1/2Unknown120 enrolled2024

    Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus

    Ministry of Health, Saudi Arabia

    Type 1 Diabetes

  • NCT07701005Completed154 enrolled2024

    Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

    Goztepe Prof Dr Suleyman Yalcın City Hospital

    Steatosis of Liver · Metabolic Liver Injury · Obesity · Overweight

  • NCT07056803Completed212 enrolled2024

    Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

    University of Palermo

    Diabetes Mellitus Type 2

  • NCT07336862Phase 1/2Recruiting200 enrolled2024

    Bariatric Surgery Combined With GLP-1 Receptor Agonists Study

    China-Japan Friendship Hospital

    Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07043361Completed5,300 enrolled2023

    Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

    Hillel Yaffe Medical Center

    Metabolic Disease

  • 2023-506300-12-00Revoked24 enrolled2023

    Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease

    Region Midtjylland

    Obesity, Non-alcoholic Fatty Liver Disease

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06042153Phase 4Active Not Recruiting43 enrolled2023

    DIALYSIS-TIR Study

    University of Texas Southwestern Medical Center

    Type 2 Diabetes · End Stage Renal Disease on Dialysis

  • NCT06131437Phase 3Completed809 enrolled2023

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    Novo Nordisk A/S

    Obesity

  • NCT05819853Phase 3Recruiting80 enrolled2023

    Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

    University of Colorado, Denver

    PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries · Obese

  • NCT06629688Completed51 enrolled2023

    Semaglutide and Intestinal Iron Absorption

    University Hospital Dubrava

    Diabetes Mellitus Type 2 · Iron Absorption

  • NCT06069622Recruiting30 enrolled2023

    Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

    Brigham and Women's Hospital

    Overweight and Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06333080Terminated1 enrolled2023

    The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin

    Aalborg University Hospital

    Diabetes Mellitus, Type 2

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06060392Recruiting50 enrolled2023

    Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

    Medanta, The Medicity, India

    Liver Transplant; Complications · Diabete Mellitus

  • NCT05938712Phase 2Recruiting20 enrolled2023

    The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

    University Health Network, Toronto

    Kidney Transplant Recipients

  • NCT06015893Phase 2Active Not Recruiting63 enrolled2023

    Semaglutide Therapy for Alcohol Reduction (STAR)

    National Institute on Drug Abuse (NIDA)

    Addiction · Alcohol Use Disorder

  • NCT05788965Phase 2/3Completed8 enrolled2023

    Semaglutide in CFRD

    University of Minnesota

    Cystic Fibrosis · Cystic Fibrosis-related Diabetes

  • NCT06298799Unknown400 enrolled2023

    GENETIC VARIABILITY TO GLP1 TREATMENT

    GENGE

    Type 2 Diabetes · Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05751720Phase 1/2Unknown30 enrolled2023

    Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

    Dr Adnan Agha

    Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis · Type 2 Diabetes · Liver Fat

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06097390Phase 1Completed121 enrolled2023

    A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

    Novo Nordisk A/S

    Healthy Participants

  • NCT06065540Phase 3Completed2,734 enrolled2023

    A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    Novo Nordisk A/S

    Type 2 Diabetes Mellitus

  • NCT06045221Phase 3Completed1,698 enrolled2023

    A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

    Eli Lilly and Company

    Type 2 Diabetes

  • NCT05813912Phase 3Completed148 enrolled2023

    A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06739044Phase 3Completed494 enrolled2023

    Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    Type 2 Diabetes

  • NCT07309094Recruiting250 enrolled2023

    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    Cardenal Herrera University

    Chronic Kidney Disease stage3 · Chronic Kidney Disease stage4 · Chronic Kidney Disease Stage 1 · Chronic Kidney Disease Stage 2

  • NCT06041217Phase 3Completed242 enrolled2023

    A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT05569772Phase 3Recruiting252 enrolled2023

    Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

    Universitaire Ziekenhuizen KU Leuven

    Glucose Intolerance After a Recent History of Gestational Diabetes

  • 2022-502082-22-00Ongoing252 enrolled2023

    S66967

    UZ Leuven

    prediabetes

  • NCT06344247Unknown48 enrolled2023

    Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

    RenJi Hospital

    Obesity · Chronic Kidney Diseases

  • 2022-502647-35-00Revoked67 enrolled2023

    MK-6024-013

    Merck Sharp & Dohme LLC

    Non-alcoholic steatohepatitis

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06974825Phase 2Completed67 enrolled2023

    A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

    BrightGene Bio-Medical Technology Co., Ltd.

    Type 2 Diabetes

  • NCT05996848Phase 3Completed300 enrolled2023

    A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Obesity or Overweight

  • NCT05996874Phase 1Completed121 enrolled2023

    A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants

    Novo Nordisk A/S

    Healthy Participants

  • NCT06256549Phase 2Unknown272 enrolled2023

    A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

    Gan and Lee Pharmaceuticals, USA

    Type 2 Diabetes

  • 2023-503949-65-00Revoked120 enrolled2023

    NN9924-4977

    Novo Nordisk A/S

    Type 2 Diabetes

  • NCT05984238Completed33 enrolled2023

    A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    Diabetes Mellitus, Type 2

  • NCT05990374Unknown100 enrolled2023

    Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

    Nanjing First Hospital, Nanjing Medical University

    Diabetes

  • NCT05897372Phase 2Terminated1 enrolled2023

    Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

    Iain Bressendorff

    Diabetic Kidney Disease

  • NCT05920889Phase 2Completed140 enrolled2023

    Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

    Chinese University of Hong Kong

    Stroke · Stroke, Acute · Stroke, Ischemic · Brain Diseases

  • NCT06005012Phase 2Active Not Recruiting120 enrolled2023

    Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

    University of California, San Diego

    Fibrosis, Liver · Type 2 Diabetes Mellitus in Obese · Non-Alcoholic Fatty Liver Disease

  • 2023-506825-13-00Revoked13 enrolled2023

    NN6535-7519

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

  • NCT05067621Phase 2Active Not Recruiting60 enrolled2023

    Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

    Yale University

    Type 2 Diabetes Mellitus · Impaired Glucose Tolerance · Non-Alcoholic Fatty Liver Disease · Obesity, Childhood

  • NCT05950516Phase 3Unknown478 enrolled2023

    Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

    Qilu Pharmaceutical Co., Ltd.

    Type 2 Diabetes

  • NCT05891587Phase 2Completed80 enrolled2023

    Semaglutide Therapy for Alcohol Reduction - Tulsa

    Oklahoma State University Center for Health Sciences

    Alcohol Use Disorder

  • NCT05726227Phase 3Active Not Recruiting210 enrolled2023

    A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Obesity

  • NCT05872022Enrolling By Invitation728 enrolled2023

    A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

    Novo Nordisk A/S

    Pregnancy · Obesity · Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2022-502922-41-00Temporarily Halted86 enrolled2023

    NN9536-4512

    Novo Nordisk A/S

    Obesity and overweight

  • NCT06354101Withdrawn2023

    The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

    CorEvitas

    Metabolic Health

  • NCT06497049Phase 1Completed120 enrolled2023

    Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

    Geropharm

    Pharmacokinetics · Safety Issues · Bioequivalence

  • NCT05877547Phase 2Completed381 enrolled2023

    A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

    Merck Sharp & Dohme LLC

    Non-alcoholic Fatty Liver Disease · Fatty Liver, Nonalcoholic · NAFLD · Nonalcoholic Fatty Liver Disease

  • NCT05819138Phase 3Recruiting60 enrolled2023

    Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

    University of Colorado, Denver

    Diabetes Mellitus, Type 1

  • NCT05891496Phase 3Completed23 enrolled2023

    A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

    Novo Nordisk A/S

    Alzheimers Disease

  • NCT06154486Completed30 enrolled2023

    Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

    Hospital Israelita Albert Einstein

    Pneumonia, Aspiration · Anesthesia

  • NCT05895643Phase 2Completed108 enrolled2023

    Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

    Psychiatric Centre Rigshospitalet

    Alcohol Abuse · Alcohol Addiction · Alcohol Dependence · Alcohol Use Disorder

  • 2023-503371-25-00Revoked108 enrolled2023

    Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

    Region Hovedstaden

    Alcohol Use Disorder

  • NCT06182618Unknown400 enrolled2023

    Retrospective Analysis for Patients With Metabolic Syndrome

    Second Affiliated Hospital, Zhejiang University, School of Medicine

    Metabolic Syndrome

  • NCT05756764Active Not Recruiting30 enrolled2023

    Anti-obesity Pharmacotherapy and Inflammation

    Louisiana State University Health Sciences Center in New Orleans

    Obesity

  • NCT06118008Phase 2Completed54 enrolled2023

    A Study of HS-20094 in T2DM Participants

    Jiangsu Hansoh Pharmaceutical Co., Ltd.

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05890976Phase 3Completed200 enrolled2023

    Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT05702905Phase 4Unknown75 enrolled2023

    Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

    Peking University First Hospital

    PCOS (Polycystic Ovary Syndrome) · Semaglutide

  • NCT06475586Phase 4Completed30 enrolled2023

    Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

    University of Banja Luka

    Psoriasis Vulgaris · Diabetes Type 2

  • NCT05209165Phase 4Suspended132 enrolled2023

    Semaglutide to Reduce Atrial Fibrillation Burden

    San Francisco Veterans Affairs Medical Center

    Atrial Fibrillation · Obesity · Overweight

  • ISRCTN1238287956 enrolled2023

    A comparison between patient obesity self-injection education using artificial-intelligence powered "clinicians" and humans

    University Hospital Galway

    Overweight and Obesity

  • NCT05870462Phase 4Unknown100 enrolled2023

    Semaglutide and Vascular Regeneration

    Canadian Medical and Surgical Knowledge Translation Research Group

    Atherosclerosis · Cardiovascular Diseases · Diabetes Mellitus, Type 2 · Obesity

  • NCT05822830Phase 3Completed751 enrolled2023

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

    Eli Lilly and Company

    Obesity · Overweight

  • NCT06215196Completed81 enrolled2023

    Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

    S.LAB (SOLOWAYS)

    Overweight and Obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05630586Phase 2Recruiting380 enrolled2023

    Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

    Aarhus University Hospital

    Acute Ischemic Stroke

  • 2022-501072-25-02Ongoing380 enrolled2023

    The safety and efficacy of acute subcutaneous administration of semaglutide in non-diabetic patients with acute ischemic stroke: a multicentre, phase 2, prospective, randomized, open-label, blinded endpoint trial (ASSET)

    Aarhus University Hospital

    Ischemic Stroke

  • NCT05537233Phase 2Completed115 enrolled2023

    ADJUnct Semaglutide Treatment in Type 1 Diabetes

    Viral N. Shah

    Type 1 Diabetes · Obesity

  • NCT05751226Phase 1Completed88 enrolled2023

    A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

    Boehringer Ingelheim

    Healthy · Obesity

  • NCT05813925Phase 3Completed331 enrolled2023

    A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Obesity or Overweight

  • NCT05786521Phase 4Completed20 enrolled2023

    Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

    The University of Texas Health Science Center at San Antonio

    Aging · Diabetes Mellitus, Type 2 · PreDiabetes · Overweight and Obesity

  • NCT06827002Phase 1/2Active Not Recruiting248 enrolled2023

    Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults

    University of Yaounde 1

    Obesity and Overweight · Appetite Regulation

  • NCT05586802Phase 3Recruiting150 enrolled2023

    Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

    Georgios Papadakis

    Klinefelter Syndrome

  • NCT05784402Phase 1Completed264 enrolled2023

    A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

    Novo Nordisk A/S

    Healthy Participants

  • NCT05441267Phase 4Active Not Recruiting21,296 enrolled2023

    A Study of Cardiovascular Events iN Diabetes Plus

    University of Oxford

    Diabetes Mellitus, Type 2

  • NCT05443568Completed155 enrolled2023

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05766709Phase 1Completed53 enrolled2023

    A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

    Novo Nordisk A/S

    Non-alcoholic Steatohepatitis

  • NCT05669755Phase 3Active Not Recruiting7,101 enrolled2023

    REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

    Novo Nordisk A/S

    Cardiovascular Disease

  • NCT05502562Completed388 enrolled2023

    A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05779644Unknown300 enrolled2023

    Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

    RenJi Hospital

    Metformin · Obesity, Abdominal · Diabetes Mellitus, Type 2 · Abdominal Fat

  • NCT05755360Completed291 enrolled2023

    DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05813249Phase 4Completed180 enrolled2023

    Semaglutide in Nonalcoholic Fatty Liver Disease

    Zagazig University

    Non-alcoholic Fatty Liver Disease

  • NCT07272343Phase 4Recruiting100 enrolled2023

    The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

    Second Affiliated Hospital of Nanchang University

    Type 2 Diabetes Mellitus (T2DM) · Semaglutide · Caloric Restriction

  • NCT05501483Recruiting60 enrolled2023

    Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

    Karolinska Institutet

    Type 2 Diabetes

  • NCT05394519Phase 3Completed1,200 enrolled2023

    A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Overweight · Obesity · Type 2 Diabetes Mellitus

  • NCT05419726Recruiting20 enrolled2023

    Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

    University of California, Los Angeles

    Obesity

  • NCT05716724Completed288 enrolled2023

    O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2024-513416-98-00Ongoing90 enrolled2023

    Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone and Semaglutide (DiaSpax)

    Karolinska University Hospital

    Diabetes type 2

  • NCT05579249Phase 4Completed500 enrolled2023

    A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

    Novo Nordisk A/S

    Obesity

  • NCT05671653Phase 1Terminated32 enrolled2023

    A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

    Pfizer

    Obesity

  • NCT05689099Phase 1Completed20 enrolled2023

    A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2 · Healthy Participants

  • NCT05700877Phase 4Recruiting7,300 enrolled2023

    Screening and Intervention for Subclinical Coronary Artery Disease in Patients With Type 2 Diabetes

    Per Løgstrup Poulsen

    Type 2 Diabetes · Cardiovascular Diseases

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2022-500143-21-01Temporarily Halted7,300 enrolled2023

    INTEN-CT

    Aarhus University Hospital, Odense University Hospital

    Type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05646706Phase 3Completed1,407 enrolled2023

    A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

    Novo Nordisk A/S

    Obesity

  • NCT05649137Phase 3Completed512 enrolled2023

    A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

    Novo Nordisk A/S

    Obesity · Diabetes Mellitus, Type 2

  • NCT05597202Phase 4Unknown22 enrolled2023

    Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    Type 2 Diabetes

  • NCT05087342Phase 3Completed119 enrolled2022

    Latino Semaglutide Study

    Loma Linda University

    Obesity · Obesity; Drug · Overweight or Obesity · Weight Loss

  • NCT05616052Phase 4Unknown80 enrolled2022

    Comparison of Body Weight Change Through Different Smeglutide Administration Methods

    Huashan Hospital

    Weight Change, Body

  • NCT05768945Completed742,670 enrolled2022

    Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

    Brigham and Women's Hospital

    Diabetes

  • ISRCTN6035867510 enrolled2022

    Oral delivery of semaglutide to the colon for improved absorption

    BDD Pharma Ltd

    Oral delivery of semaglutide to the colon

  • NCT05616013Phase 2Completed507 enrolled2022

    Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

    Eli Lilly and Company

    Obesity · Obese · Overweight or Obesity

  • NCT05567796Phase 3Active Not Recruiting3,400 enrolled2022

    A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

    Novo Nordisk A/S

    Obesity

  • NCT05073835Phase 3Active Not Recruiting70 enrolled2022

    Semaglutide 2.4 mg in Patients With Poor Weight-loss

    University College, London

    Obesity · Diabetes · Metabolic Syndrome

  • NCT05579977Phase 2Terminated902 enrolled2022

    Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

    Pfizer

    Diabetes Mellitus · Obesity

  • NCT05195944Phase 4Enrolling By Invitation58 enrolled2022

    Semaglutide vs Sitagliptin

    University Health Network, Toronto

    Liver Transplant; Complications · Diabetes Mellitus · NASH - Nonalcoholic Steatohepatitis · NAFLD

  • NCT05443191Completed50 enrolled2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05254314Phase 2Active Not Recruiting100 enrolled2022

    Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

    Vanderbilt University Medical Center

    Asthma

  • NCT05564117Phase 3Completed307 enrolled2022

    Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT05530577Phase 2Completed24 enrolled2022

    Effects of Semaglutide on Nicotine Intake

    University of North Carolina, Chapel Hill

    Tobacco Use Disorder · Nicotine Addiction

  • NCT05444153Phase 3Withdrawn2022

    Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04885634Phase 3Withdrawn2022

    Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

    Axel Brandes

    Atrial Fibrillation · Overweight and Obesity

  • NCT05473286Withdrawn2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2022-500311-39-00Ongoing352 enrolled2022

    S62015

    UZ Leuven

    Patients with Crohn's disease undergoing surgery and having at least one risk factor for postoperative recurrence of the disease.

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05371496Phase 4Completed81 enrolled2022

    Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

    Mayo Clinic

    Cardiomyopathy · Heart Failure With Preserved Ejection Fraction (HFpEF) · Obesity

  • NCT06027567Phase 4Completed38 enrolled2022

    The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

    Rigmor Højland Jensen

    Idiopathic Intracranial Hypertension · Intracranial Pressure · Obesity · Pseudotumor Cerebri Syndrome

  • NCT05520775Phase 2Completed48 enrolled2022

    Semaglutide for Alcohol Use Disorder

    University of North Carolina, Chapel Hill

    Alcohol Use Disorder · Cigarette Smoking

  • 2024-517120-19-02Revoked50 enrolled2022

    Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

    Rigshospitalet

    Idiopathic Intracranial Hypertension

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05302596Phase 2Completed16 enrolled2022

    Semaglutide Use in Elderly Obese Patients

    State University of New York at Buffalo

    Obesity · Aging

  • NCT05340868Recruiting1,000 enrolled2022

    Genetics of the Acute Response to Oral Semaglutide

    Medical University of Bialystok

    PreDiabetes · Prediabetic State · Obesity

  • NCT05514535Phase 3Completed573 enrolled2022

    A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2 · Obesity

  • NCT04998136Phase 3Completed150 enrolled2022

    Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

    Novo Nordisk A/S

    Obesity

  • ISRCTN7128387188 enrolled2022

    Does semaglutide change the build up of Alzheimer's disease proteins in people at risk?

    Imperial College London

    Alzheimer's disease

  • NCT05498610Phase 1Completed24 enrolled2022

    A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05486065Phase 2Completed245 enrolled2022

    A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05478252Phase 3Completed388 enrolled2022

    A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05443334Completed465 enrolled2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05548647Phase 4Completed120 enrolled2022

    Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

    University of Pennsylvania

    Obesity

  • NCT05816057Phase 3Completed476 enrolled2022

    A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

    Hangzhou Jiuyuan Gene Engineering Co. Ltd.,

    Diabetes Mellitus, Type 2

  • NCT05305794Phase 3Recruiting76 enrolled2022

    Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

    Centre Hospitalier Universitaire Dijon

    Double Diabetes

  • NCT05442450Phase 4Unknown116 enrolled2022

    Efficacy of Oral Semaglutide in Overweight or Obesity

    Asian Institute of Gastroenterology, India

    Obesity · Weight Loss

  • NCT05468632Completed314 enrolled2022

    A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT07732218Phase 4Completed95 enrolled2022

    Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial

    Rehman Medical Institute - RMI

    Type 2 Diabetes

  • NCT04174755Recruiting80 enrolled2022

    Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

    University College Dublin

    Obesity · HIV-1-infection

  • NCT05429593Phase 1Completed152 enrolled2022

    A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

    Novo Nordisk A/S

    Healthy Volunteers

  • NCT05435677Phase 1Completed20 enrolled2022

    A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2022-500007-52-00Revoked138 enrolled2022

    NN9917-4751

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2024-513168-24-00Ongoing80 enrolled2022

    Semaglutide_2019

    University College Dublin

    HIV & Obesity

  • NCT05574439Phase 4Completed246 enrolled2022

    Young Adults With Early-onset Obesity Treated With Semaglutide

    Signe Torekov

    Obesity, Adolescent

  • NCT05356104Phase 2Recruiting110 enrolled2022

    GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

    Chinese University of Hong Kong

    Cerebral Small Vessel Disease

  • NCT05333003Active Not Recruiting92 enrolled2022

    Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

    Centre for Addiction and Mental Health

    Schizophrenia Spectrum Disorders

  • NCT06820047Completed190 enrolled2022

    Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study

    University of Roma La Sapienza

    Obesity and Obesity-related Medical Conditions

  • NCT05147896Unknown100 enrolled2022

    Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

    University Medical Centre Ljubljana

    Diabetes Mellitus, Type 2 · Atherosclerosis

  • NCT05533632Phase 4Completed104 enrolled2022

    Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05230589Completed194 enrolled2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • ISRCTN13040627400 enrolled2022

    Can semaglutide, a GLP-1 agonist, which mimics a hormone that regulates appetite and blood sugar levels, help non-obese people achieve and maintain weight loss

    Sharon Giese, MD

    Weight loss and the benefits

  • NCT05259033Phase 3Completed683 enrolled2022

    A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05071898Phase 1Recruiting600 enrolled2022

    Pharmacogenetics of Response to GLP1R Agonists

    University of Maryland, Baltimore

    Obesity · Diabetes Type 2

  • NCT05316662Completed187 enrolled2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05230615Completed458 enrolled2022

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04873245Phase 2Completed120 enrolled2022

    Lifestyle Counseling and Medication for Adolescent Weight Management

    University of Minnesota

    Obesity, Childhood

  • NCT04889183Phase 3Completed125 enrolled2022

    SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

    University Medical Center Groningen

    Obesity · Albuminuria

  • NCT05249881Early Phase 1Unknown300 enrolled2022

    "Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

    Aga Khan University

    Diabetes Mellitus, Type 2 · Weight Change, Body

  • NCT05303857Phase 4Completed107 enrolled2022

    Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

    University of Erlangen-Nürnberg Medical School

    Diabetes Mellitus, Type 2

  • NCT06301191Unknown50 enrolled2022

    The Effect of Semaglutide on Cardiovascular Markers and Liver Function

    Attikon Hospital

    Diabetes Type 2

  • NCT07457424Active Not Recruiting140 enrolled2022

    Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)

    University College Dublin

    Metabolic Disease · Obesity & Overweight

  • NCT04854083Phase 4Unknown50 enrolled2022

    Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

    Kirsi Pietiläinen

    Type2 Diabetes

  • NCT05236517Phase 1Completed60 enrolled2022

    A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

    Novo Nordisk A/S

    Obesity

  • NCT05227196Phase 1Completed546 enrolled2022

    A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

    Novo Nordisk A/S

    Healthy Volunteers · Type 2 Diabetes

  • NCT04938388Phase 4Terminated12 enrolled2022

    Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

    Sansum Diabetes Research Institute

    Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders (Including Diabetes Mellitus)

  • NCT05078255Completed61 enrolled2022

    The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

    Asger Lund, MD

    Type 2 Diabetes · Obesity

  • NCT05232708Phase 1Completed18 enrolled2022

    A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

    Novo Nordisk A/S

    Healthy Volunteers (Diabetes Mellitus, Type 2)

  • NCT04873050Phase 4Recruiting102 enrolled2022

    Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

    Woman's

    Pre Diabetes · Postpartum Disorder

  • NCT06118203Completed18 enrolled2022

    Semaglutide Use in Acute Pulmonary Embolism

    Imperial College London

    Pulmonary Embolism

  • NCT05193578Phase 2Completed154 enrolled2022

    Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

    Jan Frystyk

    Schizophrenia · Prediabetic State

  • NCT04979130Phase 4Completed69 enrolled2022

    Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

    University of Colorado, Denver

    Type 2 Diabetes · Chronic Inflammation · Intestinal Permeability

  • NCT05857085Phase 4Completed90 enrolled2021

    Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

    General and Teaching Hospital Celje

    Endothelial Dysfunction · Diabetes Mellitus, Type 1 · Biomarkers · Endothelial Progenitor Cells

  • NCT05153564Phase 1Completed27 enrolled2021

    A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05173714Phase 2Recruiting156 enrolled2021

    Sit Less, Interact and Move More (SLIMM) 2 Study

    Srinvasan Beddhu

    Chronic Kidney Diseases · Obesity

  • NCT05144984Phase 2Completed500 enrolled2021

    A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05119179Phase 4Recruiting300 enrolled2021

    Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

    The University of Texas Health Science Center, Houston

    PreDiabetes

  • NCT05132088Phase 3Completed201 enrolled2021

    Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

    Novo Nordisk A/S

    Overweight and Obesity

  • NCT05129891Phase 1Completed384 enrolled2021

    A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

    Novo Nordisk A/S

    Healthy Volunteers · High Blood Cholesterol Levels · Type 2 Diabetes

  • NCT05071417Phase 3Unknown120 enrolled2021

    Effect Of Semaglutide In Coronary Atheroma Plaque

    Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

    Atheroscleroses, Coronary

  • NCT04466345Phase 2Completed72 enrolled2021

    Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

    University Health Network, Toronto

    Major Depressive Disorder

  • NCT05064735Phase 3Completed407 enrolled2021

    Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

    Novo Nordisk A/S

    Obesity

  • NCT05606471Phase 4Unknown45 enrolled2021

    Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

    University of Nottingham

    Type 2 Diabetes Mellitus in Obese

  • NCT05035095Phase 3Completed667 enrolled2021

    Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

    Novo Nordisk A/S

    Obesity · Overweight

  • NCT04615871Phase 2Unknown400 enrolled2021

    Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

    Vladimír Džavík

    Covid19 · Myocardial Injury

  • NCT04817644Phase 1Completed14 enrolled2021

    A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05046873Phase 1Completed16 enrolled2021

    A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05040971Phase 3Completed207 enrolled2021

    Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

    Novo Nordisk A/S

    Obesity

  • NCT05035082Phase 4Completed1,018 enrolled2021

    A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04892199Phase 4Active Not Recruiting104 enrolled2021

    Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

    Anders Fink-Jensen, MD, DMSci

    Metabolic Disturbance · Schizophrenia · Type 2 Diabetes · Clozapine

  • NCT05040087Active Not Recruiting127 enrolled2021

    Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

    Foundation for Atlanta Veterans Education and Research, Inc.

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05016882Phase 2Completed698 enrolled2021

    Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

    Novo Nordisk A/S

    Non-alcoholic Steatohepatitis

  • 2023-506961-74-00Revoked165 enrolled2021

    NN9500-4656

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

  • NCT04624672Phase 4Terminated3 enrolled2021

    Treatment of GLP-1 for Diabetic Bariatric Patients

    Geisinger Clinic

    Diabetes Mellitus, Type 2

  • NCT04971785Phase 2Completed457 enrolled2021

    Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

    Gilead Sciences

    Nonalcoholic Steatohepatitis

  • NCT04944992Phase 2Completed145 enrolled2021

    A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

    Merck Sharp & Dohme LLC

    Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis

  • NCT04982575Phase 2Completed92 enrolled2021

    Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT05220917Active Not Recruiting781,430 enrolled2021

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital

    Cardiovascular Events · Type2 Diabetes · Renal Disease

  • NCT04741074Phase 3Terminated15 enrolled2021

    Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

    Geisinger Clinic

    CKD · Diabetic Kidney Disease · Type 2 Diabetes Mellitus in Obese · Obesity

  • NCT04969939Phase 2Completed120 enrolled2021

    A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

    Novo Nordisk A/S

    Obesity

  • NCT04940078Phase 1Completed40 enrolled2021

    A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

    Novo Nordisk A/S

    Obesity & Overweight

  • NCT05577728Completed2,316 enrolled2021

    Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

    Brigham and Women's Hospital

    Diabetes Mellitus, Type 2

  • NCT04990024Recruiting60 enrolled2021

    The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide

    American University of Beirut Medical Center

    Obesity · Weight Loss

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04916470Phase 3Completed617 enrolled2021

    Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

    Novo Nordisk A/S

    Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

  • NCT04865744Phase 4Completed10 enrolled2021

    The Effect of Semaglutide on Pituitary Function

    University of Tartu

    Healthy

  • NCT04777396Phase 3Completed1,840 enrolled2021

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

    Novo Nordisk A/S

    Early Alzheimer's Disease

  • NCT04777409Phase 3Completed1,840 enrolled2021

    A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

    Novo Nordisk A/S

    Early Alzheimer´s Disease

  • NCT04878406Phase 1Completed24 enrolled2021

    A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

  • 2023-506919-18-00Revoked873 enrolled2021

    NN6535-4730

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

  • 2023-506918-45-00Revoked798 enrolled2021

    NN6535-4725

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

  • NCT04862923Completed336 enrolled2021

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04878393Completed650 enrolled2021

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04865770Phase 3Completed106 enrolled2021

    A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2 · Chronic Kidney Disease

  • NCT04822181Phase 3Active Not Recruiting1,205 enrolled2021

    Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

    Novo Nordisk A/S

    Non-alcoholic Steatohepatitis

  • 2023-506962-30-00Temporarily Halted219 enrolled2021

    NN9931-4553

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

  • NCT04639414Phase 4Completed192 enrolled2021

    Combined Active Treatment in Type 2 Diabetes With NASH

    German Diabetes Center

    Type 2 Diabetes · Non-alcoholic Steatohepatitis (NASH) · Non-alcoholic Fatty Liver Disease (NAFLD)

  • NCT04702516Phase 1/2Unknown64 enrolled2021

    The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture

    Morten Frost

    Osteopenia

  • NCT04788511Phase 3Completed529 enrolled2021

    Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

    Novo Nordisk A/S

    Obesity

  • NCT04216589Phase 2Completed51 enrolled2021

    Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

    National Institute of Allergy and Infectious Diseases (NIAID)

    HIV Infections · Non-Alcoholic Fatty Liver Disease

  • NCT04779697Phase 1Completed96 enrolled2021

    GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

    Yale University

    Obesity

  • NCT04572165Completed194,928 enrolled2021

    Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04538352Phase 4Completed60 enrolled2021

    Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

    The Cleveland Clinic

    Type 2 Diabetes

  • NCT04707469Phase 3Completed1,606 enrolled2021

    Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04251156Phase 3Completed375 enrolled2020

    Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

    Novo Nordisk A/S

    Overweight · Obesity · Diabetes Mellitus, Type 2

  • NCT04601740Completed145 enrolled2020

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04601753Completed194 enrolled2020

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04596631Phase 3Completed132 enrolled2020

    A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • 2023-506923-27-00Revoked20 enrolled2020

    NN9924-4437

    Novo Nordisk A/S

    Type 2 diabetes

  • NCT04559815Completed194 enrolled2020

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04560998Phase 3Completed792 enrolled2020

    A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2 · Peripheral Arterial Disease

  • NCT04524832Phase 1Completed290 enrolled2020

    Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT06489457Phase 3Completed25 enrolled2020

    The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

    University Medical Centre Ljubljana

    Type 2 Diabetes Mellitus · Obesity · Functional Hypogonadism

  • NCT04451837Phase 2Active Not Recruiting200 enrolled2020

    Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

    Region Skane

    Type2 Diabetes

  • NCT04515849Phase 2Completed248 enrolled2020

    A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

    AstraZeneca

    Type 2 Diabetes Mellitus · Chronic Kidney Diseases

  • NCT04537637Completed99 enrolled2020

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04513704Phase 1Completed156 enrolled2020

    A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

  • NCT04537624Completed194 enrolled2020

    A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04469855Completed3,217 enrolled2020

    Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04153929Phase 2Completed413 enrolled2020

    A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

  • NCT04287179Phase 3Withdrawn2020

    SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04447859Phase 3Unknown100 enrolled2020

    16-week Flexible vs. 8-week Semaglutide Titration

    Tel-Aviv Sourasky Medical Center

    Diabetes type2

  • NCT04259801Phase 1Completed152 enrolled2020

    First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

    Novo Nordisk A/S

    Healthy Volunteers · Overweight · Obesity · Diabetes Mellitus, Type 2

  • NCT04261933Completed789 enrolled2020

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04238962Phase 1Completed111 enrolled2020

    A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT05503927Enrolling By Invitation2,701 enrolled2020

    A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

    Novo Nordisk A/S

    Pregnancy · Obesity · Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04228354Phase 1Completed28 enrolled2020

    A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide

    Novo Nordisk A/S

    Healthy Volunteers · Overweight · Obesity

  • NCT04175665Completed1,133 enrolled2020

    Real-world Health Outcomes in Canadian Patients Using Semaglutide

    LMC Diabetes & Endocrinology Ltd.

    Type 2 Diabetes

  • NCT04187300Phase 1Completed68 enrolled2019

    A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT04383197Unknown30 enrolled2019

    Exercise and GLP-1 RA on Insulin Secretion

    University of Copenhagen

    Type 2 Diabetes

  • NCT04189848Phase 4Completed104 enrolled2019

    Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

    Novo Nordisk A/S

    Healthy Volunteers · Diabetes Mellitus, Type 2 · Overweight · Obesity

  • NCT04152915Phase 1Completed68 enrolled2019

    A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

    Novo Nordisk A/S

    Healthy Volunteers · Diabetes Mellitus, Type 2

  • NCT04263415Phase 4Completed30 enrolled2019

    The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

    University Medical Centre Ljubljana

    PCOS · Semaglutide · Taste, Altered · Tongue Tissue Transcriptome

  • NCT04061200Phase 4Unknown80 enrolled2019

    Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

    Steno Diabetes Center Copenhagen

    Type 2 Diabetes With Renal Manifestations

  • NCT04143945Phase 2Completed104 enrolled2019

    A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

    Novo Nordisk A/S

    Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity

  • NCT04094415Completed581 enrolled2019

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04016974Phase 1Completed32 enrolled2019

    A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

    Novo Nordisk A/S

    Healthy Volunteers · Diabetes Mellitus, Type 2

  • NCT04102189Phase 3Completed201 enrolled2019

    A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT04109508Phase 1Completed278 enrolled2019

    A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

    Novo Nordisk A/S

    Healthy Volunteers · Type 2 Diabetes

  • NCT04109547Phase 3Completed521 enrolled2019

    A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04097600Phase 1Completed274 enrolled2019

    A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

    Novo Nordisk A/S

    Healthy Volunteers · Type 2 Diabetes

  • NCT04200625Completed80 enrolled2019

    Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

    University of Miami

    Epicardial Fat

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT04083820Completed521 enrolled2019

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04074161Phase 3Completed338 enrolled2019

    Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT04032197Phase 1Completed101 enrolled2019

    A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04067999Completed230 enrolled2019

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04126603Phase 4Completed10 enrolled2019

    Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

    Sabyasachi Sen

    Diabetes Mellitus, Type 2

  • NCT03987919Phase 3Completed1,879 enrolled2019

    A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

    Eli Lilly and Company

    Type 2 Diabetes

  • NCT03987074Phase 2Completed109 enrolled2019

    Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

    Gilead Sciences

    Nonalcoholic Steatohepatitis

  • NCT04017832Phase 3Completed1,441 enrolled2019

    A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03884075Phase 2Recruiting104 enrolled2019

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Non-Alcoholic Steatohepatitis · Non-Alcoholic Fatty Liver Disease

  • NCT04012255Phase 1Terminated29 enrolled2019

    A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03951753Phase 1Completed117 enrolled2019

    A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

  • NCT04007107Phase 2Completed103 enrolled2019

    A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

    Novo Nordisk A/S

    Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity

  • NCT03989232Phase 3Completed961 enrolled2019

    A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03987451Phase 2Completed71 enrolled2019

    A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

    Novo Nordisk A/S

    Non-alcoholic Steatohepatitis

  • NCT03914326Phase 3Completed9,651 enrolled2019

    A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03819153Phase 3Completed3,533 enrolled2019

    A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03929679Completed218 enrolled2019

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT04019197Phase 2Active Not Recruiting108 enrolled2019

    Effects of Semaglutide in HIV-Associated Lipohypertrophy

    Case Western Reserve University

    HIV/AIDS · Lipohypertrophy · Obesity

  • NCT03811561Phase 3Active Not Recruiting1,500 enrolled2019

    A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03919929Phase 2/3Completed60 enrolled2019

    Treating PCOS With Semaglutide vs Active Lifestyle Intervention

    University of Colorado, Denver

    PCOS · Adolescent Obesity · NAFLD

  • 2023-506827-26-00Temporarily Halted589 enrolled2019

    NN9535-4352

    Novo Nordisk A/S

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

  • NCT03899402Phase 2/3Active Not Recruiting78 enrolled2019

    Triple Therapy in T1DM

    State University of New York at Buffalo

    Type 1 Diabetes Mellitus

  • NCT03876015Completed215 enrolled2019

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03985384Phase 4Completed140 enrolled2019

    Semaglutide Treatment On Coronary Progression

    Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Type 2 Diabetes · Coronary Artery Disease

  • NCT03842202Phase 1Completed72 enrolled2019

    A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03811574Phase 3Completed401 enrolled2019

    STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03789578Phase 1Completed30 enrolled2019

    A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03659682Phase 2Unknown120 enrolled2019

    GLP1R in Parkinson's Disease

    Oslo University Hospital

    Parkinson Disease

  • NCT03574597Phase 3Completed17,604 enrolled2018

    Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03724981Phase 4Completed312 enrolled2018

    A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

  • NCT03292315Phase 4Completed5 enrolled2018

    Once Weekly GLP-1 in Persons With Spinal Cord Injury

    James J. Peters Veterans Affairs Medical Center

    Spinal Cord Injuries · Insulin Resistance · Pre Diabetes · Obesity

  • NCT03707990Phase 1Completed88 enrolled2018

    A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

    Novo Nordisk A/S

    Obesity and Overweight

  • NCT03693430Phase 3Completed304 enrolled2018

    Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03689374Phase 3Completed2,274 enrolled2018

    A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03631186Completed215 enrolled2018

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03648281Completed333 enrolled2018

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03638778Phase 1Completed105 enrolled2018

    Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03611322Phase 1Completed54 enrolled2018

    A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03611582Phase 3Completed611 enrolled2018

    Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

    Novo Nordisk A/S

    Overweight · Obesity

  • NCT03600480Phase 1Completed96 enrolled2018

    A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

    Novo Nordisk A/S

    Obesity · Overweight

  • NCT03598621Phase 1Completed68 enrolled2018

    A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03596450Phase 4Completed1,278 enrolled2018

    Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03574584Phase 1Completed37 enrolled2018

    A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

    Novo Nordisk A/S

    Metabolism and Nutrition Disorders · Overweight or Obesity

  • NCT03548935Phase 3Completed1,961 enrolled2018

    STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

    Novo Nordisk A/S

    Metabolism and Nutrition Disorder · Overweight or Obesity

  • NCT03548987Phase 3Completed902 enrolled2018

    Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

    Novo Nordisk A/S

    Metabolism and Nutrition Disorder · Obesity

  • NCT03552757Phase 3Completed1,210 enrolled2018

    Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

    Novo Nordisk A/S

    Obesity · Overweight

  • NCT03457012Completed462 enrolled2018

    A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

    Novo Nordisk A/S

    Diabetes Mellitus, Type 2

  • NCT03466567Phase 1Completed21 enrolled2018

    A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03357380Phase 1Completed67 enrolled2017

    A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

    Novo Nordisk A/S

    Hepatobiliary Disorders · Non-alcoholic Fatty Liver Disease

  • NCT03288740Phase 1Completed36 enrolled2017

    A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03061214Phase 3Completed868 enrolled2017

    Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03191396Phase 3Completed577 enrolled2017

    Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03086330Phase 3Completed302 enrolled2017

    Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03136484Phase 3Completed788 enrolled2017

    Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03021187Phase 3Completed731 enrolled2017

    Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02692716Phase 3Completed3,183 enrolled2017

    A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03018028Phase 3Completed243 enrolled2017

    Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03015220Phase 3Completed458 enrolled2017

    Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03010475Phase 1Completed41 enrolled2017

    A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02970942Phase 2Completed320 enrolled2016

    Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

    Novo Nordisk A/S

    Hepatobiliary Disorders · Non-alcoholic Steatohepatitis

  • NCT02920385Phase 1Completed45 enrolled2016

    A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02906930Phase 3Completed703 enrolled2016

    Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02827708Phase 3Completed324 enrolled2016

    Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02849080Phase 3Completed504 enrolled2016

    Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02877355Phase 1Completed55 enrolled2016

    Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02863419Phase 3Completed711 enrolled2016

    Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02863328Phase 3Completed822 enrolled2016

    Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02845219Phase 1Completed25 enrolled2016

    A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02773381Phase 1Completed15 enrolled2016

    A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02607865Phase 3Completed1,864 enrolled2016

    Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02648204Phase 3Completed1,201 enrolled2016

    Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02453711Phase 2Completed957 enrolled2015

    Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

    Novo Nordisk A/S

    Metabolism and Nutrition Disorder · Obesity

  • NCT02461589Phase 2Completed706 enrolled2015

    Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02557620Phase 1Completed113 enrolled2015

    Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02305381Phase 3Completed397 enrolled2014

    Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02254291Phase 3Completed308 enrolled2014

    A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02249871Phase 1Completed54 enrolled2014

    Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02249910Phase 1Completed32 enrolled2014

    Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02243098Phase 1Completed31 enrolled2014

    Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02231684Phase 1Completed42 enrolled2014

    Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02212067Phase 1Completed87 enrolled2014

    A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02210871Phase 1Completed44 enrolled2014

    Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Hepatic Impaired

  • NCT02207374Phase 3Completed601 enrolled2014

    A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02128932Phase 3Completed1,089 enrolled2014

    Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02161588Phase 1Completed48 enrolled2014

    A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT02172313Phase 1Completed78 enrolled2014

    Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02147431Phase 1Completed38 enrolled2014

    A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02146079Phase 1Completed44 enrolled2014

    A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT02079870Phase 1Completed30 enrolled2014

    Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

    Novo Nordisk A/S

    Diabetes · Metabolism and Nutrition Disorder · Obesity

  • NCT02070510Phase 1Completed52 enrolled2014

    A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02064348Phase 1Completed168 enrolled2014

    A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02060266Phase 1Completed7 enrolled2014

    Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT02054897Phase 3Completed388 enrolled2014

    Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT02022254Phase 1Completed24 enrolled2013

    Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT02016911Phase 1Completed56 enrolled2013

    Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT02014259Phase 1Completed71 enrolled2013

    Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT01885208Phase 3Completed813 enrolled2013

    Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01930188Phase 3Completed1,231 enrolled2013

    Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01923181Phase 2Completed632 enrolled2013

    Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01866748Phase 1Completed170 enrolled2013

    Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT01720446Phase 3Completed3,297 enrolled2013

    Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01766245Phase 1Completed28 enrolled2012

    A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT01686945Phase 1Completed107 enrolled2012

    Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT01619345Phase 1Completed27 enrolled2012

    Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT01572753Phase 1Completed161 enrolled2012

    Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT01324505Phase 1Completed43 enrolled2011

    Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01272973Phase 1Completed96 enrolled2011

    Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT00833716Phase 1Completed62 enrolled2009

    Effect of Renal Impairment on the Pharmacokinetics of NN9535

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Renal Impairment

  • NCT00851773Phase 1Completed84 enrolled2009

    Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

    Novo Nordisk A/S

    Diabetes · Healthy

  • NCT00813020Phase 1Completed44 enrolled2009

    A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT00696657Phase 2Completed415 enrolled2008

    A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT03144271Phase 1Completed58 enrolled2007

    Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2 · Healthy

  • NCT07677865Completed213,891 enrolled2007

    GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

    West China Hospital

    Alzheimer Disease · Diabetes Mellitus Type 2 · Obesity & Overweight

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06863363Phase 4Not Yet Recruiting212 enrolled

    PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults

    Shanghai Zhongshan Hospital

    Non-diabetic Obesity

  • 2024-511114-20-00Authorised, Not Started50 enrolled

    49RC23_0307

    Centre Hospitalier Universitaire D'Angers

    Craniopharyngioma

  • 2023-504159-29-0011104 enrolled

    Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation

    Rigshospitalet

    Hyperglycaemia after renal transplantation

  • 2024-518746-24-00Revoked104 enrolled

    Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?

    Psykiatrisk Center Kobenhavn

    Schizophrenia

  • 2023-504988-16-00Authorised, Not Started16 enrolled

    IKEM-ISS-02

    Institut Klinicke A Experimentalni Mediciny

    Obesity

  • 2025-523977-40-00Authorised, Not Started90 enrolled

    ARMYDA - 10

    Azienda Ospedaliero-Universitaria Maggiore Della Carita

    non-ST-elevation myocardial infarction (NSTEMI); unstable angina, diabetes mellitus

  • 2025-522486-29-01Authorised, Not Started212 enrolled

    Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

    Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

  • 2024-517463-23-00Authorised, Not Started80 enrolled

    Weight management with orismilast alone or in combination with s.c. semaglutide (WELOSITI)

    Gentofte Hospital

    obesity

  • 2025-523374-17-03Authorised, Not Started60 enrolled

    PI24/01356

    Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

    Type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-523374-17-011160 enrolled

    PI24/01356

    Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

    Type 2 diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2024-519235-42-00Authorised, Not Started1 enrolled

    MSGLP/GAMS

    Comenius University Bratislava

    Patients with confirmed multiple sclerosis (MS), with worse prognosis given the higher disease activity, in productive age between 18 and 60 years, with EDSS<5, who at the time of investigation are on baseline therapy of the disease for at least 3 months

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2026-526016-36-00Authorised, Not Started96 enrolled

    SEM-BEAT

    UZ Leuven

    obesity

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-520802-37-00Authorised, Not Started80 enrolled

    STABLE-GLP1

    Universita' Degli Studi Di Napoli Federico II

    Type 2 diabetes mellitus

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • 2025-524819-37-00Authorised, Not Started345 enrolled

    RAPHAEL

    Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

    obstructive sleep apnea

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Semaglutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.